WO2015120280A1 - Methods of treating alzheimer's disease - Google Patents
Methods of treating alzheimer's disease Download PDFInfo
- Publication number
- WO2015120280A1 WO2015120280A1 PCT/US2015/014829 US2015014829W WO2015120280A1 WO 2015120280 A1 WO2015120280 A1 WO 2015120280A1 US 2015014829 W US2015014829 W US 2015014829W WO 2015120280 A1 WO2015120280 A1 WO 2015120280A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- seq
- patient
- polymorphism
- hvr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- Methods of treating patients suffering from mild to moderate Alzheimer's Disease using antibodies that target amyloid ⁇ are provided. Also provided are methods of selecting or identifying patients for treatment with antibodies that target amyloid ⁇ . Methods include the use of prognostic and/or predictive biomarkers.
- AD Alzheimer's Disease
- MMSE Mini-Mental State Examination
- Approved medical therapies that inhibit acetylcholinesterase (“AChE”) activity or antagonize N-methyl-D-aspartate receptors in the brain may temporarily improve the symptoms of AD in some patients but do not modify the progression of the disease (Cummings, N. Engl. J. Med. 2004; 351 :56-67).
- AChE acetylcholinesterase
- patients who carry the ApoE4 allele may represent an etiologically distinct population of patients with AD.
- amyloid plaques in the brain are a hallmark pathologic finding in AD, first reported by Alois Alzheimer in 1906.
- These amyloid plaques are primarily composed of Abeta peptides (Haass and Selkoe, Nature 2007; 8:656-67) generated by the sequential cleavage of amyloid precursor protein ("APP") via ⁇ and ⁇ - secretase activity.
- Abeta particularly in its oligomerized forms, is toxic to neurons and is believed to be causative in AD.
- Therapies that reduce Abeta levels in the brain may alleviate cognitive dysfunction and block further synaptic loss, axon degeneration, and neuronal cell death.
- Abeta can be transported actively across the blood-brain barrier (Deane et al. , Stroke 2004; 35(Suppl I):2628-31).
- systemic delivery of antibodies to Abeta increases Abeta levels in plasma while reducing levels in the central nervous system (CNS) through several proposed mechanisms, including dissolution of brain Abeta plaque, phagocytic removal of opsonized Abeta, and finally via efflux of Abeta from the brain as a result of an equilibrium shift of Abeta resulting from circulating antibodies (Morgan, Neurodegener. Dis. 2005; 2:261-6).
- bapineuzumab did appear to stabilize plaque levels and decreased phosphorylated tau levels in cerebrospinal fluid - suggesting that modification of these biomarkers alone is not necessarily predictive of clinical efficacy (Miles et al., Scientific Reports 2013; 3: 1-4).
- solanezumab an antibody specific for monomeric Abeta that binds in the middle portion of the peptide, the primary cognitive and functional endpoints were not met (Eli Lilly and Company press release dated August 24, 2012, "Eli Lilly and Company Aanounces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer's Disease").
- AD Alzheimer's Disease Facts and Figures, Alzheimer's and Dementia 9:2.
- AD is the sixth-leading cause of death in the United States as of 2013 (id.).
- Current approved therapies treat only some of the symptoms of AD, and not the underlying degeneration.
- Crenezumab (also known as MABT5102A) is a fully humanized IgG4 monoclonal antibody to Abeta selected for its ability to bind both monomeric and oligomeric forms of Abeta in vitro. Crenezumab binds both Abetal-40 and Abeta 1-42, inhibits Abeta
- crenezumab is a human IgG4 backbone antibody, it has reduced Fey receptor ("Fc R") binding affinity compared with human IgGl or IgG2, which is predictive of reduced immune effector response.
- Fc R Fey receptor
- the effect is seen in patients having a brain amyloid load that is typically seen in patients diagnosed with AD. Additionally, the results demonstrate that these effects occur without significant incidence of adverse events such as ARIA-E and ARIA-H.
- This application thus provides methods for treating and monitoring patients diagnosed with mild to moderate AD, especially mild AD, and ApoE4 positive patients, as well as patients having brain amyloid accumulation that is typically seen in patients diagnosed with AD.
- a humanized monoclonal anti-amyloid beta antibody with a conformational epitope specific for the middle region of amyloid beta ( ⁇ ) peptide is effective to treat mild to moderate AD, especially ApoE4 positive patients and patients with milder forms of AD, such as, but not limited to, mild AD, without an increased incidence of ARIA-E or ARIA-H.
- this application provides therapeutic agents for modulating the severity of AD and improved methods of using the same.
- the present application provides methods of treating patients suffering from AD and other amyloidoses, comprising administering a humanized
- ⁇ or Abeta monoclonal anti-amyloid beta ( ⁇ or Abeta) antibody, or antigen-binding fragment thereof, that binds within residues 13 and 24 of amyloid ⁇ (1-42)(SEQ ID NO: l).
- the antibody, or antigen-binding fragment thereof is capable of binding fibrillar, oligomeric, and monomeric forms of Abeta.
- the antibody is an IgG4 antibody.
- the antibody, or antigen-binding fragment thereof comprises six hypervariable regions (HVRs) wherein HVR-H1 is SEQ ID NO:2, HVR-H2 is SEQ ID NO:3, HVR-H3 is SEQ ID NO:4, HVR-L1 is SEQ ID NO:6, HVR-L2 is SEQ ID NO:7, and HVR-L3 is SEQ ID NO:8.
- HVRs hypervariable regions
- the antibody, or antigen-binding fragment thereof comprises a heavy chain having the amino acid sequence of SEQ ID NO:5, comprising a heavy chain variable region, and a light chain having the amino acid sequence of SEQ ID NO:9, comprising a light chain variable region.
- the antibody is crenezumab.
- Suitable patients include patients suffering from mild to moderate AD, patients with an MMSE score of 18 to 26, patients suffering from mild AD, patients with an MMSE score of 20 or above (e.g., 20-30, 20-26, 24- 30, 21-26, 22-26, 22-28, 23-26, 24-26, or 25-26), patients suffering from early AD (including patients having mild cognitive impairement due to AD and patients having preclinical AD), amyloid positive patients (or patients having brain amyloid load consistent with that seen in patients diagnosed with AD), and ApoE4 positive patients suffering from mild to moderate or mild AD.
- the methods provided herein are methods of reducing decline due to AD in patients suffering from early, mild, or mild to moderate AD.
- the decline is one or more of: clinical decline, cognitive decline, and functional decline.
- the decline is clinical decline.
- the decline is a decline in cognitive capacity or cognitive decline.
- the decline comprises a decline in functional capacity or functional decline.
- Various tests and scales have been developed to measure cognitive capacity (including memory) and/or function.
- one or more test is used to measure clinical, functional, or cognitive decline.
- a standard measurement of cognitive capacity is the Alzheimer's Disease
- the reduction or slowing in decline in cognitive capacity (or cognitive decline) in patients being treated with the antibodies of the invention is determined using the ADAS-Cogl2 test.
- An increase in ADAS-Cogl2 score is indicative of worsening in a patient's condition.
- the reduction or slowing in cognitive decline (or decline in cognitive capacity) in patients being treated with the antibodies of the invention is determined by a Clinical Dementia Rating Scale / Sum of Boxes (CDR-SOB) score.
- CDR-SOB Clinical Dementia Rating Scale / Sum of Boxes
- reduction or slowing in functional decline (or decline in functional ability) in patients being treated with the antibodies of the invention is determined using the Instrumental Activities of Daily Living (or iADL) scale. In some embodiments, decline of one or more types is assessed and one or more of the foregoing tests or scales is used to measure reduction or slowing in decline.
- An antibody, or antigen-binding fragment thereof, of the invention is administered at a dose that is effective to treat the AD or other amyloidosis, as described herein.
- Suitable dosages are described herein and can range from about 0.3 mg/kg to 100 mg/kg.
- the dosage is 15 mg/kg.
- the dosage is 30 mg/kg.
- the dosage is 45 mg/kg.
- the dosage is between 500 mg and lOOOmg, for example 500 mg, 700 mg, 720 mg, 750 mg, 800 mg, 820 mg, 900 mg, or between 1000 mg and 2500 mg, for example 1050 mg, 1500 mg, or 2100 mg.
- a variety of dosage regimens are contemplated including dosage regimens in which the antibody is administered repeatedly, e.g., on a weekly or monthly schedule, over an extended period of time, e.g., months to years.
- the humanized monoclonal anti- Abeta antibody of the present disclosure provides a further benefit in that it does not increase the incidence of adverse events such as ARIA-E and ARIA-H. As shown herein, there was no increase in these adverse events in the treatment arm relative to the placebo arm. Thus, the present disclosure further provides methods of treating patients suffering from mild to moderate AD or mild AD without increasing the incidence of adverse events such as ARIA-E and/or ARIA-H.
- the present application provides methods of treating patients having early, mild to moderate, or mild AD, comprising administering to a patient suffering from early AD, mild AD, or mild to moderate AD, a humanized monoclonal anti- amyloid beta ( ⁇ ) antibody in an amount effective to treat the AD, wherein the patient has at least one CLUSTERIN allele that comprises a T at the single nucleotide polymorphism (SNP) rs 1532278 or an equivalent allele thereof.
- the CLUSTERIN allele is an equivalent allele.
- the CLUSTERIN allele is in linkage disequilibrium to rsl532278.
- the equivalent allele comprises a SNP in linkage disequilibrium to rsl532278.
- the linkage disequilibrium is a D' measure or an r measure.
- the D' measure between the selected SNP and the alternate SNP is > 0.60.
- the D' measure between the selected SNP and the alternate SNP is > 0.70, 0.80 or 0.90.
- the D' measure between the selected SNP and the alternate SNP is 1.0.
- the r measure between the selected SNP and the alternate SNP is > 0.60.
- the r measure between the selected SNP and the alternate SNP is > 0.70, 0.80 or 0.90.
- the r measure between the selected SNP and the alternate SNP is 1.0.
- the methods of treating patients suffering from AD and other amyloidoses comprise administering a humanized monoclonal anti-amyloid beta ( ⁇ or Abeta) antibody, or antigen-binding fragment thereof, that binds within residues 13 and 24 of amyloid ⁇ (1-42)(SEQ ID NO: l).
- the antibody, or antigen-binding fragment thereof is capable of binding fibrillar, oligomeric, and monomeric forms of Abeta.
- the antibody is an IgG4 antibody.
- the antibody, or antigen-binding fragment thereof comprises six hypervariable regions (HVRs) wherein HVR-H1 is SEQ ID NO:2, HVR-H2 is SEQ ID NO:3, HVR-H3 is SEQ ID NO:4, HVR-L1 is SEQ ID NO:6, HVR-L2 is SEQ ID NO:7, and HVR-L3 is SEQ ID NO:8.
- HVR-H1 is SEQ ID NO:2
- HVR-H3 is SEQ ID NO:4
- HVR-L1 is SEQ ID NO:6
- HVR-L2 is SEQ ID NO:7
- HVR-L3 is SEQ ID NO:8.
- the antibody, or antigen-binding fragment thereof comprises a heavy chain having the amino acid sequence of SEQ ID NO:5, comprising a heavy chain variable region, and a light chain having the amino acid sequence of SEQ ID NO:9, comprising a light chain variable region.
- the antibody is crenezumab.
- An antibody, or antigen-binding fragment thereof, of the invention is administered at a dose that is effective to treat the AD or other amyloidosis, as described herein.
- Suitable dosages are described herein and can range from about 0.3 mg/kg to 100 mg/kg.
- the dosage is 15 mg/kg.
- the dosage is 30 mg/kg.
- the dosage is 45 mg/kg.
- the dosage is between 500 mg and lOOOmg, for example 500 mg, 700 mg, 720 mg, 750 mg, 800 mg, 820 mg, 900 mg, or between 1000 mg and 2500 mg, for example 1050 mg, 1500 mg, or 2100 mg.
- a variety of dosage regimens are contemplated including dosage regimens in which the antibody is administered repeatedly, e.g., on a weekly or monthly schedule, over an extended period of time, e.g., months to years.
- Suitable patients include patients suffering from mild to moderate AD, patients with an MMSE score of 18 to 26, patients suffering from mild AD, patients with an MMSE score of 20 or above ⁇ e.g., 20-30, 20-26, 24- 30, 21-26, 22-26, 22-28, 23-26, 24-26, or 25-26), patients suffering from early AD (including patients having mild cognitive impairement due to AD and patients having preclinical AD), amyloid positive patients (or patients having brain amyloid load consistent with that seen in patients diagnosed with AD), and ApoE4 positive patients suffering from mild to moderate or mild AD.
- kits for identifying patients who are likely to benefit from treatment with a humanized monoclonal anti-amyloid beta ( ⁇ ) antibody as well as methods of selecting patients for treatment with a humanized monoclonal anti-amyloid beta ( ⁇ ) antibody, or antigen-binding fragment thereof.
- the methods comprise detecting in a sample from the patient presence or absence of a CLUSTERIN allele having a T at a single nucleotide polymorphism (SNP) rs 1532278, or equivalent allele thereof.
- SNP single nucleotide polymorphism
- the methods of identifying a patient comprise detecting in a sample from the patient presence of a CLUSTERIN allele comprising a polymorphism predictive of a response to treatment with a humanized monoclonal anti-amyloid beta ( ⁇ ) antibody. In some embodiments, the methods comprise selecting a patient as more likely to respond to said treatment when a T at the single nucleotide polymorphism (SNP) rsl532278 is present in a sample from the patient.
- SNP single nucleotide polymorphism
- the CLUSTERIN allele is an equivalent allele.
- the CLUSTERIN allele is in linkage disequilibrium to rsl532278.
- the equivalent allele comprises a SNP in linkage disequilibrium to rsl532278.
- the linkage disequilibrium is a D' measure or an r measure.
- the D' measure between the selected SNP and the alternate SNP is > 0.60.
- the D' measure between the selected SNP and the alternate SNP is > 0.70, 0.80 or 0.90.
- the D' measure between the selected SNP and the alternate SNP is 1.0.
- the r measure between the selected SNP and the alternate SNP is > 0.60. In some embodiments the r measure between the selected SNP and the alternate SNP is > 0.70, 0.80 or 0.90. In some embodiments, the r measure between the selected SNP and the alternate SNP is 1.0.
- a humanized monoclonal anti-amyloid beta ( ⁇ or Abeta) antibody, or antigen-binding fragment thereof binds within residues 13 and 24 of amyloid ⁇ (1-42)(SEQ ID NO: l).
- the antibody, or antigen-binding fragment thereof is capable of binding fibrillar, oligomeric, and monomeric forms of Abeta.
- the antibody is an IgG4 antibody.
- the antibody, or antigen-binding fragment thereof comprises six hypervariable regions (HVRs) wherein HVR-Hl is SEQ ID NO:2, HVR-H2 is SEQ ID NO:3, HVR-H3 is SEQ ID NO:4, HVR-Ll is SEQ ID NO:6, HVR-L2 is SEQ ID NO:7, and HVR-L3 is SEQ ID NO:8.
- the antibody, or antigen-binding fragment thereof comprises a heavy chain having the amino acid sequence of SEQ ID NO:5, comprising a heavy chain variable region, and a light chain having the amino acid sequence of SEQ ID NO:9, comprising a light chain variable region.
- the antibody is crenezumab.
- the antibody is selected from the group consisting of solanezumab, bapineuzumab, aducanumab and gantenerumab.
- the disclosure provides methods of predicting whether an individual suffering from AD is likely to respond to treatment comprising an anti-Abeta antibody, or antigen-binding fragment thereof.
- the methods comprise determining the identity of a nucleotide at SNP rsl532278 in a sample from the individual and predicting an increased likelihood of responding to treatment comprising an anti-Abeta antibody, or antigen-binding fragment thereof, when the sample contains at least one allele with a T nucleotide at SNP rsl532278, or an equivalent allele thereof.
- the equivalent allele comprises a SNP in linkage disequilibrium to rsl532278.
- the linkage disequilibrium is a D' measure or an r measure.
- the D' measure between the selected SNP and the alternate SNP is > 0.60. In some embodiments, the D' measure between the selected SNP and the alternate SNP is > 0.70, 0.80 or 0.90. In some embodiments, the D' measure between the selected SNP and the alternate SNP is 1.0. In some embodiments, the r measure between the selected SNP and the alternate SNP is > 0.60. In some embodiments the r measure between the selected SNP and the alternate SNP is > 0.70, 0.80 or 0.90. In some embodiments, the r measure between the selected SNP and the alternate SNP is 1.0.
- the anti-Abeta antibody is a humanized monoclonal anti- amyloid beta ( ⁇ or Abeta) antibody, or antigen-binding fragment thereof.
- the humanized monoclonal anti-amyloid beta ( ⁇ or Abeta) antibody, or antigen-binding fragment thereof binds within residues 13 and 24 of amyloid ⁇ (1-42)(SEQ ID NO: l).
- the antibody, or antigen-binding fragment thereof is capable of binding fibrillar, oligomeric, and monomeric forms of Abeta.
- the antibody is an IgG4 antibody.
- the antibody, or antigen-binding fragment thereof comprises six hypervariable regions (HVRs) wherein HVR-Hl is SEQ ID NO:2, HVR-H2 is SEQ ID NO:3, HVR-H3 is SEQ ID NO:4, HVR-Ll is SEQ ID NO:6, HVR-L2 is SEQ ID NO:7, and HVR-L3 is SEQ ID NO:8.
- the antibody, or antigen-binding fragment thereof comprises a heavy chain having the amino acid sequence of SEQ ID NO:5, comprising a heavy chain variable region, and a light chain having the amino acid sequence of SEQ ID NO:9, comprising a light chain variable region.
- the antibody is crenezumab.
- the antibody is selected from the group consisting of solanezumab, bapineuzumab, aducanumab and gantenerumab.
- the present disclosure provides methods of optimizing therapeutic efficacy for treatment of AD comprising: determining the genotype of a patient, wherein a patient who is determined to carry at least one CLUSTERIN allele with a T nucleotide at SNP rs 1532278, or an equivalent allele thereof, is more likely to respond to treatment with an anti- Abeta antibody, or antigen-binding fragment thereof.
- the genotype of a patient wherein a patient who is determined to carry at least one CLUSTERIN allele with a T nucleotide at SNP rs 1532278, or an equivalent allele thereof, is more likely to respond to treatment with an anti- Abeta antibody, or antigen-binding fragment thereof.
- CLUSTERIN allele is an equivalent allele.
- the CLUSTERIN allele is in linkage disequilibrium to rsl532278.
- the equivalent allele comprises a SNP in linkage disequilibrium to rsl532278.
- the linkage disequilibrium is a D' measure or an r measure.
- the D' measure between the selected SNP and the alternate SNP is > 0.60.
- the D' measure between the selected SNP and the alternate SNP is > 0.70, 0.80 or 0.90.
- the D' measure between the selected SNP and the alternate SNP is 1.0.
- the r measure between the selected SNP and the alternate SNP is > 0.60. In some embodiments the r measure between the selected SNP and the alternate SNP is > 0.70, 0.80 or 0.90. In some embodiments, the r measure between the selected SNP and the alternate SNP is 1.0.
- the anti-Abeta antibody is a humanized monoclonal anti- amyloid beta ( ⁇ or Abeta) antibody, or antigen-binding fragment thereof.
- the humanized monoclonal anti-amyloid beta ( ⁇ or Abeta) antibody, or antigen-binding fragment thereof binds within residues 13 and 24 of amyloid ⁇ (1-42)(SEQ ID NO: l).
- the antibody, or antigen-binding fragment thereof is capable of binding fibrillar, oligomeric, and monomeric forms of Abeta.
- the antibody is an IgG4 antibody.
- the antibody, or antigen-binding fragment thereof comprises six hypervariable regions (HVRs) wherein HVR-Hl is SEQ ID NO:2, HVR-H2 is SEQ ID NO:3, HVR-H3 is SEQ ID NO:4, HVR-Ll is SEQ ID NO:6, HVR-L2 is SEQ ID NO:7, and HVR-L3 is SEQ ID NO:8.
- HVRs hypervariable regions
- the antibody, or antigen-binding fragment thereof comprises a heavy chain having the amino acid sequence of SEQ ID NO:5, comprising a heavy chain variable region, and a light chain having the amino acid sequence of SEQ ID NO:9, comprising a light chain variable region.
- the antibody is crenezumab.
- the antibody is selected from the group consisting of solanezumab, bapineuzumab, aducanumab and gantenerumab.
- the methods provided herein comprise detecting the presence, and/or determining the identity, of a CLUSTERIN allele, or equivalent allele thereof.
- presence of a CLUSTERIN allele in an individual comprises determining the identity of the nucleotide at the polymorphism from nucleic acid provided from a sample from an individual.
- the nucleic acid sample comprises DNA.
- the nucleic acid sample comprises R A.
- the nucleic acid sample is amplified.
- the nucleic acid sample is amplified by a polymerase chain reaction.
- the polymorphism is detected by polymerase chain reaction or sequencing.
- the polymorphism is detected by amplification of a target region containing at least one polymorphism, and hybridization with at least one sequence-specific oligonucleotide that hybridizes under stringent conditions to at least one polymorphism and detecting the hybridization.
- the polymorphism is detected by a technique selected from the group consisting of scanning probe and nanopore DNA sequencing, pyrosequencing, Denaturing Gradient Gel Electrophoresis (DGGE),
- Temporal Temperature Gradient Electrophoresis TTGE
- Zn(II)-cyclen polyacrylamide gel electrophoresis Zn(II)-cyclen polyacrylamide gel electrophoresis
- homogeneous fluorescent PCR-based single nucleotide polymorphism analysis phosphate-affinity polyacrylamide gel electrophoresis
- high-throughput SNP genotyping platforms molecular beacons, 5 'nuclease reaction, Taqman assay, MassArray (single base primer extension coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry), trityl mass tags, genotyping platforms (such as the Invader Assay®), single base primer extension (SBE) assays, PCR amplification (e.g.
- the identity of the nucleotide at the polymorphism in a patient is determined via genotyping.
- the genotyping is performed by PCR analysis, sequence analysis or LCR analysis.
- the sample is any biological sample from which genomic DNA may be isolated, for example, but not to be limited to a tissue sample, a sample of saliva, a cheek swab sample, blood, or other biological fluids that contain genomic DNA.
- the sample comprises DNA.
- the sample comprises RNA.
- the present disclosure further provides pharmaceutical formulations suitable for use in the methods of treatment disclosed herein.
- the pharmaceutical formulations can be formulated for any convenient route of administration, e.g., parenteral or intravenous injection, and will typically include, in addition to the anti-Abeta of the present disclosure, one or more acceptable carriers, excipients, and/or diluents suited to the desired mode of administration.
- an antibody of the invention may be formulated for intravenous administration.
- an antibody of the invention may be formulated in an arginine buffer, e.g., an arginine succinate buffer.
- the buffer can contain one or more surfactants, e.g., a polysorbate.
- the buffer concentration is 50 mM or greater.
- the pH is between 4.5 and 7.0, e.g., pH 5.5. Further embodiments are described herein.
- the pharmaceutical formulations can be package in unit dosage forms for ease of use.
- Treatment with anti-Abeta antibodies for treatment of AD or other amyloidosis can be combined with other therapy, including one or more anti-Abeta antibodies other than crenezumab.
- other therapy include neurological drugs, corticosteroids, antibiotics, and antiviral agents.
- anti-Abeta antibodies other than crenezumab include solanezumab, bapineuzumab, aducanumab, and gantenerumab.
- kits for determining the presence of a CLUSTERIN allele comprising reagents and instructions for detecting the presence of at least one polymorphism in CLUSTERIN, wherein the
- polymorphism is an allele comprising SNP rsl532278 or an equivalent allele. Reagents and methods of using the kit are further described herein.
- agents for use in such methods include agents that are capable of detecting a CLUSTERIN allele with a T nucleotide at SNP rs 1532278, or an equivalent allele thereof.
- FIG 1 provides the amino acid sequence of Abeta(l-42) (SEQ ID NO: 1) with amino acids 13 to 24 underlined.
- FIG 2 provides the amino acid sequence of three heavy chain hypervariable regions (HVR-H1, HVR-H2, and HVR-H3, respectively) and the amino acid sequence of three light chain regions (HVR-L1, HVR-L2, HVR-L3, respectively).
- FIG 3 provides the amino acid sequence of heavy chain (SEQ ID NO:5), comprising the heavy chain variable region spanning amino acids 1 to 112 of SEQ ID NO:5, and light chain (SEQ ID NO:9), comprising the light chain variable region spanning amino acids 1 to 112 of SEQ ID NO:9, of crenezumab.
- the underlining in SEQ ID NOs:5 and 9 shows the amino acid sequences of the three heavy chain HVR corresponding to SEQ ID NOs:2-4 and the three light chain HVR corresponding to SEQ ID NOs:6-8, respectively.
- FIG 4A-B provides a summary of the patients enrolled in the clinical trial described in Example 1 , tabulating the number of patients enrolled in each arm (treatment versus placebo), ApoE4 status (ApoE4 negative/ ApoE4 positive), stage of AD (mild or moderate), and MMSE scores at screening, existence and type of concurrent therapy (conmed use) for AD symptoms.
- FIG 5 provides a schematic of the clinical trials described in Example 1, showing the dosing schedule, amount, and route.
- FIG 6A-B provide data tables showing the change in ADAS-Cogl2 scores at 73 weeks relative to baseline, in the treatment arm and the placebo arm.
- FIG 6A provides data for patients with mild to moderate AD, mild AD, moderate AD, and ApoE4 positive and negative patients.
- FIG 6B provides data for patients according to MMSE score.
- FIG 7 provides a chart of the change in ADAS-Cogl2 scores for patients with mild AD having an MMSE score between 20 and 26, treated with crenezumab (dark solid line) or placebo (light solid line).
- FIG 8 provides a chart of the change in ADAS-Cogl2 scores for patients with mild to moderate AD having an MMSE score between 18 and 26 treated with crenezumab (dark solid line) or placebo (light solid line).
- FIG 9 provides a chart of the change in ADAS-Cogl2 scores for ApoE4 positive patients with mild-to-moderate AD treated with crenezumab (dark solid line) or placebo (light solid line).
- FIG 10 provides a chart of the change in ADAS-Cogl2 scores across all ApoE4 positive patients and patients with mild AD treated with crenezumab (dark solid line) or placebo (light solid line).
- FIG 11 provides a chart of the change in ADAS-Cogl2 scores for patients with mild AD having an MMSE score between 22 and 26, treated with crenezumab or placebo.
- FIG 12A-B provide data tables showing the change in CDR-SOB scores at 73 weeks relative to baseline, in the treatment arm and the placebo arm.
- FIG 12A provides data for the change in CDR-SOB scores for patients according to MMSE score.
- FIG 12B provides data for the change in CDR-SOB scores for patients according to MMSE score.
- CDR-SOB scores provides data for CDR-SOB scores as well as CDR Judgment and Problem solving scores and CDR Memory scores for patients with MMSE scores ranging from 18-26, 20-26, and 22-26.
- FIG 13 provides a chart of the change in CDR-SOB scores for patients with mild AD, having an MMSE score of 25 or 26, treated with crenezumab or placebo as indicated.
- FIG 14A-B provides a summary of the patients enrolled in the clinical trial described in Example 2 at baseline and after treatment, including adverse event data (A) and a timeline showing when PET scans, MRI scans, and CSF sampling was performed in the clinical trial (B).
- FIG 15A-B provides charts showing amyloid levels in patients receiving placebo (dashed line) or crenezumab (solid line), as measured by imaging of florbetapir by PET analysis (A) and CSF Abeta levels levels in patients receiving placebo or crenezumab (B).
- FIG 16A-B provides side-by-side charts showing the change in ADAS-Cogl2 scores of patients with mild to moderate AD in the treatment arm or the placebo arm.
- Chart (A) shows patient who were SNP negative (i.e., patients without any allele of the
- FIG 17A-B provides side-by-side charts showing the change in ADAS-Cogl2 scores of ApoE4 positive patients with mild to moderate AD in the treatment arm or the placebo arm.
- Chart (A) shows patient who were SNP negative (i.e., patients without any allele of the CLUSTERIN gene bearing a T at the single nucleotide polymorphism (SNP) rsl532278) and chart (B) shows patients who were SNP positive (i.e., patients with at least one allele of the CLUSTERIN gene bearing a T at the single nucleotide polymorphism (SNP) rsl532278).
- SNP single nucleotide polymorphism
- FIG 18A-B provides side-by-side charts showing the change in ADAS-Cogl2 scores of patients with mild AD in the treatment arm or the placebo arm.
- Chart (A) shows patient who were SNP negative (i.e., patients without any allele of the CLUSTERIN gene bearing a T at the single nucleotide polymorphism (SNP) rsl532278) and chart (B) shows patients who were SNP positive (i.e., patients with at least one allele of the CLUSTERIN gene bearing a T at the single nucleotide polymorphism (SNP) rsl532278).
- SNP negative i.e., patients without any allele of the CLUSTERIN gene bearing a T at the single nucleotide polymorphism (SNP) rsl532278
- SNP positive i.e., patients with at least one allele of the CLUSTERIN gene bearing a T at the single nucleotide polymorphism (SNP)
- Ranges provided in the specification and appended claims include both end points and all points between the end points.
- a range of 2.0 to 3.0 includes 2.0, 3.0, and all points between 2.0 and 3.0.
- the difference between the two values is less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10% as a function of the value for the reference/comparator antibody.
- sample refers to a composition that is obtained or derived from a subject of interest that contains a cellular and/or other molecular entity that is to be characterized and/or identified, for example based on physical,
- the definition encompasses blood and other liquid samples of biological origin and tissue samples such as a biopsy specimen or tissue cultures or cells derived therefrom.
- the source of the tissue sample may be solid tissue as from a fresh, frozen and/or preserved organ or tissue sample or biopsy or aspirate; blood or any blood constituents; bodily fluids; and cells from any time in gestation or development of the subject or plasma.
- tissue sample as used herein includes, but is not limited to, blood, serum, plasma, sputum, tissue biopsies (e.g., lung samples), and nasal samples including nasal swabs or nasal polyps.
- sample biological sample,' or “test sample” includes biological samples that have been manipulated in any way after their procurement, such as by treatment with reagents, solubilization, or enrichment for certain components, such as proteins or polynucleotides, or embedding in a semi-solid or solid matrix for sectioning purposes.
- a "section" of a tissue sample is meant a single part or piece of a tissue sample, e.g. a thin slice of tissue or cells cut from a tissue sample.
- Samples include, but are not limited to, whole blood, blood-derived cells, serum, plasma, lymph fluid, synovial fluid, cellular extracts, and combinations thereof.
- the sample is a clinical sample.
- the sample is used in a diagnostic assay.
- a sample is obtained from a subject or patient prior to treatment with an anti-Abeta antibody. In another embodiment, a sample is obtained from a subject or patient following at least one treatment with an anti-Abeta antibody.
- a "reference sample,” as used herein, refers to any sample, standard, or level that is used for comparison purposes.
- a reference sample is obtained from a healthy and/or non-diseased part of the body (e.g., tissue or cells) of the same subject or patient.
- a reference sample is obtained from an untreated tissue and/or cell of the body of the same subject or patient.
- a reference sample is obtained from a healthy and/or non-diseased part of the body (e.g., tissues or cells) of an individual who is not the subject or patient.
- a reference sample is obtained from an untreated tissue and/or cell part of the body of an individual who is not the subject or patient.
- a reference sample is a single sample or combined multiple samples from the same subject or patient that are obtained at one or more different time points than when the test sample is obtained. For example, a reference sample is obtained at an earlier time point from the same subject or patient than when the test sample is obtained.
- a reference sample includes all types of biological samples as defined above under the term "sample” that is obtained from one or more individuals who is not the subject or patient.
- a reference sample is obtained from one or more individuals with amyloidosis, e.g., Alzheimer's Disease, who is not the subject or patient.
- a reference sample is a combined multiple samples from one or more healthy individuals who are not the subject or patient.
- a reference sample is a combined multiple samples from one or more individuals with a disease or disorder (e.g., amyloidosis such as, for example, Alzheimer's Disease) who are not the subject or patient.
- a reference sample is pooled R A samples from normal tissues or pooled plasma or serum samples from one or more individuals who are not the subject or patient.
- a nucleic acid sample is isolated from a biological sample obtained from a subject.
- the nucleic acid sample may be isolated form a biological sample using standard techniques.
- the nucleic acid sample may be used in a method for determining the presence of a polymorphic variant.
- the presence or absence of a polymorphic variant may be determined using one or both chromosomal complements represented in the nucleic acid sample. Determining the presence or absence of the polymorphic variant in both
- chromosomal complements represented in the nucleic acid sample is useful for determining the zygosity of an individual for the polymorphic variant.
- small molecule refers to an organic molecule having a molecular weight between 50 Daltons to 2500 Daltons.
- antibody and “immunoglobulin” (“Ig”) are used interchangeably in the broadest sense and include, but are not limited to, monoclonal antibodies (for example, full length or intact monoclonal antibodies), polyclonal antibodies, multivalent antibodies, antibodies with polyepitopic specificity, single chain antibodies, multi-specific antibodies (for example, bispecific antibodies, trispecific antibodies, tetraspecific antibodies), and fragments of antibodies, provided they exhibit the desired biological activity.
- Such antibodies can be chimeric, humanized, human, synthetic, and/or affinity matured. Such antibodies and methods of generating them are described in more detail herein.
- Antibody fragments comprise only a portion of an intact antibody, wherein the portion preferably retains at least one, and typically most or all, of the functions normally associated with that portion when present in an intact antibody.
- an antibody fragment comprises an antigen binding site of the intact antibody and thus retains the ability to bind antigen.
- an antibody fragment for example one that comprises the Fc region, retains at least one of the biological functions normally associated with the Fc region when present in an intact antibody, such as FcRn binding, antibody half life modulation, ADCC function and complement binding.
- an antibody fragment is a monovalent antibody that has an in vivo half life substantially similar to an intact antibody.
- an antibody fragment may comprise an antigen binding arm linked to an Fc sequence capable of conferring in vivo stability to the fragment.
- antibody fragments include but are not limited to Fv, Fab, Fab', Fab'- SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules ⁇ e.g. scFv); and multispecific antibodies formed from antibody fragments.
- target refers to any native molecule from any vertebrate source, including mammals such as primates ⁇ e.g. humans) and rodents ⁇ e.g., mice and rats), unless otherwise indicated.
- the term encompasses "full-length,” unprocessed target as well as any form of target that results from processing in the cell.
- the term also encompasses naturally occurring variants of targets, e.g., splice variants or allelic variants.
- amyloid beta refers to the fragment of amyloid precursor protein (“APP) that is produced upon ⁇ -secretase 1 (“BACE1”) cleavage of APP, as well as modifications, fragments and any functional equivalents thereof, including, but not limited to, ⁇ 1-40, and ⁇ 1-42.
- APP amyloid precursor protein
- BACE1 ⁇ -secretase 1
- ⁇ is known to exist in monomeric form, as well as to associate to form oligomers and fibril structures, which may be found as constituent members of amyloid plaque.
- ⁇ peptides are well known to one of ordinary skill in the art and methods of producing said peptides or of extracting them from brain and other tissues are described, for example, in Glenner and Wong, Biochem Biophys Res. Comm. 129: 885-890 (1984). Moreover, ⁇ peptides are also commercially available in various forms.
- An exemplary amino acid sequence of human ⁇ 1-42 is D AEFRHD S G YE VHHQKLVFF AED VGSNKGAIIGLMVGGVVIA (SEQ ID NO: 1).
- anti-target antibody and "an antibody that binds to target” refer to an antibody that is capable of binding the target with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting the target.
- the extent of binding of an anti-target antibody to an unrelated, non-target protein is less than about 10% of the binding of the antibody to target as measured, e.g., by a radioimmunoassay (RIA) or biacore assay.
- RIA radioimmunoassay
- an antibody that binds to a target has a dissociation constant (Kd) of ⁇ ⁇ , ⁇ 100 nM, ⁇ 10 nM, ⁇ 1 nM, ⁇ 0.1 nM, ⁇ 0.01 nM, or ⁇ 0.001 nM (e.g., 10 ⁇ 8 M or less, e.g., from 10 ⁇ 8 M to 10 "13 M, e.g., from 10 "9 M to 10 "13 M).
- Kd dissociation constant
- an anti-target antibody binds to an epitope of a target that is conserved among different species.
- Anti-Abeta immunoglobulin refers to an antibody that specifically binds to human Abeta.
- a nonlimiting example of an anti-Abeta antibody is crenezumab.
- Other non- limiting examples of anti-Abeta antibodies are solanezumab, bapineuzumab, aducanumab, and gantenerumab.
- crenezumab and “MABT5102A” are used interchangeably herein, and refer to a specific anti-Abeta antibody that binds to monomeric, oligomeric, and fibril forms of Abeta, and which is associated with CAS registry number 1095207.
- such antibody comprises HVR region sequences set forth in FIG 2.
- such antibody comprises: (1) an HVR-H1 comprising the amino acid sequence SEQ ID NO: 2; (2) an HVR-H2 sequence comprising the amino acid sequence SEQ ID NO: 3; (3) an HVR-H3 sequence comprising the amino acid sequence SEQ ID NO: 4; (4) an HVR-L1 sequence comprising the amino acid sequence SEQ ID NO: 6; (5) an HVR-L2 sequence comprising the amino acid sequence SEQ ID NO: 7; and (6) an HVR-L3 sequence comprising the amino acid sequence SEQ ID NO: 8.
- the specific anti-Abeta antibody comprises VH and VL domains having the amino acid sequences set forth in FIG 3.
- such specific anti-Abeta antibody comprises a VH domain comprising the amino acid sequence SEQ ID NO: 5 and a VL domain comprising the amino acid sequence SEQ ID NO: 9.
- the antibody is an IgG4 antibody.
- the IgG4 antibody comprises a mutation in its constant domain such that serine 228 is instead a proline.
- amyloidosis refers to a group of diseases and disorders caused by or associated with amyloid or amyloid-like proteins and includes, but is not limited to, diseases and disorders caused by the presence or activity of amyloid-like proteins in monomeric, fibril, or polymeric state, or any combination of the three, including by amyloid plaques.
- Such diseases include, but are not limited to, secondary amyloidosis and age-related amyloidosis, such as diseases including, but not limited to, neurological disorders such as Alzheimer's Disease (“AD"), diseases or conditions characterized by a loss of cognitive memory capacity such as, for example, mild cognitive impairment (MCI), Lewy body dementia, Down's syndrome, hereditary cerebral hemorrhage with amyloidosis (Dutch type), the Guam Parkinson-Demential complex and other diseases which are based on or associated with amyloid-like proteins such as progressive supranuclear palsy, multiple sclerosis, Creutzfeld Jacob disease, Parkinson's disease, HIV-related dementia, ALS (amyotropic lateral sclerosis), inclusion-body myositis (IBM), adult onset diabetes, endocrine tumor and senile cardiac amyloidosis, and various eye diseases including macular degeneration, drusen- related optic neuropathy, glaucoma, and cataract due to beta-amyloid deposition.
- Glaucoma is a group of diseases of the optic nerve involving loss of retinal ganglion cells (RGCs) in a characteristic pattern of optic neuropathy.
- RGCs are the nerve cells that transmit visual signals from the eye to the brain.
- Caspase-3 and Caspase-8 two major enzymes in the apoptotic process, are activated in the process leading to apoptosis of RGCs.
- Caspase-3 cleaves amyloid precursor protein (APP) to produce neurotoxic fragments, including Abeta. Without the protective effect of APP, Abeta accumulation in the retinal ganglion cell layer results in the death of RGCs and irreversible loss of vision.
- APP amyloid precursor protein
- Glaucoma is often, but not always, accompanied by an increased eye pressure, which may be a result of blockage of the circulation of aqueous, or its drainage.
- raised intraocular pressure is a significant risk factor for developing glaucoma
- no threshold of intraocular pressure can be defined which would be determinative for causing glaucoma.
- the damage may also be caused by poor blood supply to the vital optic nerve fibers, a weakness in the structure of the nerve, and/or a problem in the health of the nerve fibers themselves.
- Untreated glaucoma leads to permanent damage of the optic nerve and resultant visual field loss, which can progress to blindness.
- glaucomas are classified as open-angle glaucomas, if the condition is chronic, or closed-angle glaucomas, if acute glaucoma occurs suddenly.
- Glaucoma usually affects both eyes, but the disease can progress more rapidly in one eye than in the other.
- COAG chronic open-angle glaucoma
- POAG primary open angle glaucoma
- IOP intraocular pressure
- Acute Angle Closure Glaucoma or closed-angle glaucoma is a relatively rare type of glaucoma characterized by a sudden increase in intraocular pressure to 35 to 80 mmHg, leading to severe pain and irreversible loss of vision.
- the sudden pressure increase is caused by the closing of the filtering angle and blockage of the drainage channels.
- Individuals with narrow angles have an increased risk for a sudden closure of the angle.
- AACG usually occurs monocularly, but the risk exists in both eyes. Age, cataract and pseudoexfoliation are also risk factors since they are associated with enlargement of the lens and crowding or narrowing of the angle.
- a sudden glaucoma attack may be associated with severe eye pain and headache, inflamed eye, nausea, vomiting, and blurry vision.
- Glaucoma is a mixture or combination of open and closed angle glaucoma. It affects patients with acute ACG whose angle opens after laser iridotomy, but who continue to require medications for IOP control, as well as patients with POAG or pseudoexfoliative glaucoma who gradually develop narrowing of the angle.
- NVG Normal tension glaucoma
- LSG low tension glaucoma
- Congenital (infantile) glaucoma is a relatively rare, inherited type of open-angle glaucoma. Insufficient development of the drainage area results in increased pressure in the eye that can lead to the loss of vision from optic nerve damage and to an enlarged eye. Early diagnosis and treatment are critical to preserve vision in infants and children affected by the disease.
- Secondary glaucoma may result from an ocular injury, inflammation in the iris of the eye (iritis), diabetes, cataract, or use of steroids in steroid-susceptible individuals.
- Secondary glaucoma may also be associated with retinal detachment or retinal vein occlusion or blockage.
- Pigmentary glaucoma is characterized by the detachment of granules of pigment from the iris. The granules cause blockage of the drainage system of the eye, leading to elevated intraocular pressure and damage to the optic nerve. Exfoliative glaucoma
- Tonometry determines the pressure in the eye by measuring the tone or firmness of its surface. Several types of tonometers are available for this test, the most common being the applanation tonometer. Pachymetry determines the thickness of the cornea which, in turn, measures intraocular pressure. Gonioscopy allows examination of the filtering angle and drainage area of the eye. Gonioscopy can also determine if abnormal blood vessels may be blocking the drainage of the aqueous fluid out of the eye. Ophthalmoscopy allows examination of the optic nerve and can detect nerve fiber layer drop or changes in the optic disc, or indentation (cupping) of this structure, which may be caused by increased intraocular pressure or axonal drop out.
- Gonioscopy is also useful in assessing damage to the nerve from poor blood flow or increased intraocular pressure.
- Visual Field testing maps the field of vision, subjectively, which may detect signs of glaucomatous damage to the optic nerve. This is represented by specific patterns of visual field loss.
- Ocular coherence tomography an objective measure of nerve fiber layer loss, is carried out by looking at the thickness of the optic nerve fiber layer (altered in glaucoma) via a differential in light transmission through damaged axonal tissue.
- an "antibody that binds to the same epitope" as a reference antibody refers to an antibody that blocks binding of the reference antibody to its antigen in a competition assay by 50% or more, and conversely, the reference antibody blocks binding of the antibody to its antigen in a competition assay by 50% or more.
- An exemplary competition assay is provided herein.
- biomarker refers generally to a molecule, including a single nucleotide polymorphism (SNP), protein, carbohydrate structure, or glycolipid, the expression of which in or on a mammalian tissue or cell can be detected by standard methods (or methods disclosed herein) and is predictive, diagnostic and/or prognostic for a
- a SNP biomarker is determined when a SNP (a binary entity) stratifies a group of individuals into responders and non-responders. For example, given a SNP with two nucleotides, a G and an A in which the A is the risk allele, carriers of the A allele (e.g. AA or GA individuals) respond to treatment whereas individuals without an A allele (e.g. GG individuals) do not respond.
- a SNP a binary entity
- Predictive biomarker identifies a subpopulation of patients who are most likely to respond to a given treatment.
- Prognostic biomarker is a marker that indicates the likely course of the disease in an untreated individual.
- single nucleotide polymorphism also referred to herein as "SNP” as used herein refers to a single base substitution within a DNA sequence that leads to genetic variability.
- a nucleotide position in a genome at which more than one base type is possible in a population is referred to herein as a "polymorphic site” or "polymorphism”.
- polymorphic site may be a nucleotide sequence of one or more nucleotides, an inserted nucleotide or nucleotide sequence, a deleted nucleotide or nucleotide sequence, or a microsatellite, for example.
- a polymorphic site that is two or more nucleotides in length may be 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more, 20 or more, 30 or more, 50 or more, 75 or more, 100 or more, 500 or more, or about 1000 nucleotides in length, where all or some of the nucleotide sequences differ within the region.
- a polymorphic site which is a single nucleotide in length is referred to herein as a SNP.
- each nucleotide sequence is referred to as a "polymorphic variant” or “nucleic acid variant”.
- Each possible variant in the DNA sequence is referred to as an "allele”.
- polymorphic variant represented in a majority of samples from a population is referred to as a "prevalent allele” or "major allele” and the polymorphic variant that is less prevalent in the population is referred to as an "uncommon allele” or "minor allele”.
- An individual who carries two prevalent alleles or two uncommon alleles is “homozygous” with respect to the polymorphism.
- An individual who carries one prevalent allele and one uncommon allele is "heterozygous” with respect to the polymorphism.
- C/G or A/T SNPs the alleles are ambiguous and dependent on the strand used to extract the data from the genotyping platform. With these C/G or A/T SNPs, the C or G nucleotide or the A or T nucleotide, respectively, may be a risk allele or a protective allele and is determined by correlation of allele
- the risk allele or effect allele may be the minor allele or major allele.
- An allele that correlates with a decreased risk (or increased likelihood of a benefit from therapy) or is associated with an odds ratio of ⁇ 1 is referred to as the "protective allele.”
- the protective allele may be the minor or the major allele.
- Equivalent allele or “surrogate allele” as used herein refers to an allele that is expected to behave similarly to a published allele and is selected based on allele frequencies 2
- the high r is > 0.6, 0.7, 0.8, 0.9 or 1.0.
- the high D' is > 0.6, 0.7, 0.8, 0.9 or 1.0.
- Linkage disequilibrium or "LD” when used herein refers to alleles at different loci that are not associated at random, i.e., not associated in proportion to their frequencies. If the alleles are in positive linkage disequilibrium, then the alleles occur together more often than expected assuming statistical independence. Conversely, if the alleles are in negative linkage disequilibrium, then the alleles occur together less often than expected assuming statistical independence.
- “Odds ratio” or “OR” when used herein refers to the ratio of the odds of the disease for individuals with the marker (allele or polymorphism) relative to the odds of the disease in individuals without the marker (allele or polymorphism).
- Haplotype when used herein refers to a group of alleles on a single chromosome that are closely enough linked to be inherited usually as a unit.
- a polymorphic variant may be detected on either or both strands of a double- stranded nucleic acid. Also, a polymorphic variant may be located within an intron or exon of a gene or within a portion of a regulatory region such as a promoter, a 5 ' untranslated region (UTR), a 3'UTR, and in DNA (e.g. genomic DNA (gDNA) and complementary DNA
- RNA e.g. mRNA, tRNA, and RRNA
- Polymorphic variations may or may not result in detectable differences in gene expression, polypeptide structure or polypeptide function.
- alterate SNP when used herein refers to a SNP that is expected to behave similarly to a selected SNP and is selected based on similar allele frequencies and has linkage disequilibrium with a selected SNP as measured by a r > 0.6 and/or D' > 0.6.
- therapeutic agent refers to any agent that is used to treat a disease, including but not limited to an agent that treats a symptom of the disease.
- treatment refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed during the course of clinical pathology.
- Desirable effects of treatment include, but are not limited to, alleviation or amelioration of one or more symptoms, diminishment of or delay in the appearance of or worsening of any direct or indirect pathological consequences of the disease, decrease of the rate of disease progression, and amelioration or palliation of the disease state.
- antibodies are used to delay development of a disease or to slow the progression of a disease.
- treatment emergent refers to an event that occurs after a first dose of a therapeutic agent is administered.
- a “treatment emergent adverse event” is an event that is identified upon or after the first dose of a treatment in a clinical study.
- Treatment regimen refers to a combination of dosage, frequency of
- Effective treatment regimen refers to a treatment regimen that will offer beneficial response to a patient receiving the treatment.
- Modifying a treatment refers to changing the treatment regimen including, changing dosage, frequency of administration, or duration of treatment, and/or addition of a second medication.
- an "effective amount” or “effective dose” of an agent refers to an amount or dose effective, for periods of time necessary, to achieve the desired result. For example, a
- terapéuticaally effective amount is an amount effective, for periods of time necessary, to treat the indicated disease, condition, clinical pathology, or symptom, i.e., to modify the course of progression of AD and/or to alleviate and/or prevent one or more symptoms of AD.
- the present invention provides methods of using the SNPs or other genetic based mechanisms as a predictive biomarker to predict response to treatment and as a prognostic biomarker to assess progression of AD, methods of using the SNPs or other genetic based mechanism to select a treatment strategy, and methods of using the SNPs or other genetic based mechanisms for patient stratification including but not limited to selecting patients for clinical studies or to make clinical treatment decisions.
- "Patient stratification” when used herein refers to genotyping of individuals to determine the likelihood of response to treatment. The genotyping is performed to identify whether the individual carries a SNP. Many methods exist for the measurement of specific SNP genotypes.
- SNP array Individuals that carry mutations in one or more SNPs may be detected at the DNA level by a variety of techniques including but not limited to SNP array, Taqman, fluorescence polarization, Sequenom (or other methods for analysis of SNPs as described herein).
- Nucleic acids for diagnosis may be obtained from a patient's cells, such as from blood, urine, saliva, tissue biopsy and autopsy material.
- the genomic DNA may be used directly for detection or may be amplified by using PCR prior to analysis of the genomic DNA or transcripts. For example, fragmented single-stranded DNA from an individual is hybridized to an array containing hundreds to thousands of immobilized unique nucleotide probe sequences.
- the nucleotide probe sequences are designed to bind to a target DNA sequence (e.g. for a SNP, an allele-specific probe is used to identify and analyze the presence or absence of the SNP).
- a detection system is used to record and interpret the hybridization signal between the immobilized probe and the DNA from the individual (either the probe or the DNA is labeled with a fluorophor that is detected and measured).
- the detection of a specific DNA sequence may be achieved by methods which include, but are not limited to, hybridization, RNAse protection, chemical cleavage, direct DNA sequencing or the use of restriction enzymes, Southern blotting of genomic DNA, in situ analysis, hybridizing a sample and control nucleic acids to high density arrays containing hundreds or thousands of oligonucleotide probes (Cronin et al, Hum Mutat, 7(3): 244-55 (1996) (or other methods for analysis of SNPs as described herein). For example, genetic mutations can be identified using microarrays (Shen et al, Mutat Res,573(l- 2): 70-82 (2005))). These genetic tests are useful for stratifying populations of individuals into subpopulations having different responsiveness to treatment of anti-Abeta.
- genotyping refers to methods of determining differences in the genetic make-up (“genotype") of an individual, including but not limited to the detection of the presence of DNA insertions or deletions, polymorphisms (SNPs or otherwise), alleles (including minor or major or risk alleles in the form of SNPs, by examining the individual's DNA sequence using analytical or biological assays (or other methods for analysis of SNPs as described herein)). For instance, the individual's DNA sequence determined by sequencing or other methodologies (for example other methods for analysis of SNPs as described herein), may be compared to another individual's sequence or a reference sequence.
- Methods of genotyping are generally known in the art (for example other methods for analysis of SNPs as described herein), including but are not limited to restriction fragment length polymorphism identification (RFLP) of genomic DNA, random amplified polymorphic detection (RAPD) of genomic DNA, amplified fragment length polymorphism detection (AFLPD), polymerase chain reaction (PCR), DNA sequencing, allele specific oligonucleotide (ASO) probes, and hybridization to DNA microarrays or beads. Similarly these techniques may be applied to analysis of transcripts that encode SNPs or other genetic factors.
- RFLP restriction fragment length polymorphism identification
- RAPD random amplified polymorphic detection
- AFLPD amplified fragment length polymorphism detection
- PCR polymerase chain reaction
- ASO allele specific oligonucleotide
- Samples can be conveniently assayed for a SNP using polymerase chain reaction (PCR) analysis, array hybridization or using DNA SNP chip microarrays, which are commercially available, including DNA microarray snapshots.
- PCR polymerase chain reaction
- a microarray can be utilized for determining whether a SNP is present or absent in a nucleic acid sample.
- a microarray may include oligonucleotides, and methods for making and using oligonucleotide microarrays suitable for diagnostic use are disclosed in US Pat. Nos.
- the genotyping may be used by clinicians to direct appropriate treatment procedures to individuals who most require them. For example, subjects in a study are genotyped and categorized into (1) a population that responds favorably to a treatment and (2) a population that does not respond significantly to a treatment, and (3) a population that responds adversely to a treatment. Based on the results, a subject is genotyped to predict whether the subject is likely to respond favorably or not to a treatment. Potential participants in clinical trials of a treatment may be screened to identify those that are most likely to respond favorably to the treatment. Thus, the effectiveness of drug treatment may be measured in individuals who respond positively to the drug.
- one embodiment is a method of selecting an individual for inclusion in a clinical trial of a treatment comprising the steps of: (a) obtaining a nucleic acid sample from an individual, (b) determining the presence of a polymorphic variant which is associated with a positive response to the treatment or a polymorphic variant which is associated with a lack of, or reduced, response to the treatment.
- the invention includes a method of selecting an individual for treatment comprising the steps of: (a) obtaining a nucleic acid sample from an individual, (b) determining the presence of a polymorphic variant which is associated with a positive response to the treatment and (c) treating the individual by administering the treatment.
- allele-specific primer or "AS primer” refers to a primer that hybridizes to more than one variant of the target sequence, but is capable of discriminating between the variants of the target sequence in that only with one of the variants, the primer is efficiently extended by the nucleic acid polymerase under suitable conditions. With other variants of the target sequence, the extension is less efficient or inefficient. Where extension is less efficient or inefficient, the signal is of substantially lesser intensity or preferably, falls below detection limit.
- allele-specific probe or "AS probe” refers to a probe that hybridizes to more than one variant of the target sequence, but is capable of discriminating between the variants of the target sequence in that only with one of the variants, a detectable signal is generated. With other variants of the target sequence, the signal is of substantially lesser intensity or preferably, falls below the detection limit.
- primary sequence refers to the sequence of nucleotides in a polynucleotide or oligonucleotide. Nucleotide modifications such as nitrogenous base modifications, sugar modifications or other backbone modifications are not a part of the primary sequence. Labels, such as chromophores conjugated to the oligonucleotides are also not a part of the primary sequence. Thus two oligonucleotides can share the same primary sequence but differ with respect to the modifications and labels.
- Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al, Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).
- Stringent conditions or “high stringency conditions”, as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1%
- 5 x SSC 0.75 M NaCl, 0.075 M sodium citrate
- 50 mM sodium phosphate pH 6.8
- Modely stringent conditions may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent that those described above.
- washing solution and hybridization conditions e.g., temperature, ionic strength and %SDS
- An example of moderately stringent conditions is overnight incubation at 37° C in a solution comprising: 20%
- binding affinity refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g. , an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, "binding affinity” refers to intrinsic binding affinity which reflects a 1 : 1 interaction between members of a binding pair (e.g., antibody and antigen binding arm).
- the affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein, any of which can be used for purposes of the present invention. Specific illustrative and exemplary embodiments for measuring binding affinity are described herein.
- An "affinity matured” antibody refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs), compared to a parent antibody which does not possess such alterations, such alterations resulting in an improvement in the affinity of the antibody for antigen.
- HVRs hypervariable regions
- the term "patient” refers to any single subject for which treatment is desired.
- the patient herein is a human.
- a "subject" herein is typically a human.
- a subject is a non-human mammal.
- Exemplary non-human mammals include laboratory, domestic, pet, sport, and stock animals, e.g., mice, cats, dogs, horses, and cows.
- the subject is eligible for treatment, e.g., displays one or more indicia of disease.
- such subject or patient is eligible for treatment for amyloidosis, e.g., AD.
- such eligible subject or patient is one that is experiencing or has experienced one or more signs, symptoms, or other indicators of AD or has been diagnosed with AD, whether, for example, newly diagnosed, previously diagnosed or at risk for developing AD.
- Diagnosis of AD may be made based on clinical history, clinical examination, and established imaging modalities.
- a "patient” or “subject” herein includes any single human subject eligible for treatment who is experiencing or has experienced one or more signs, symptoms, or other indicators of AD. Intended to be included as a subject are any subjects involved in clinical research trials, or subjects involved in epidemiological studies, or subjects once used as controls. The subject may have been previously treated with an anti-Abeta antibody, or antigen-binding fragment thereof, or another drug, or not so treated.
- the subject may be naive to an additional drug(s) being used when the treatment herein is started, i.e., the subject may not have been previously treated with, for example, a therapy other than anti-Abeta at "baseline" (i.e., at a set point in time before the administration of a first dose of anti-Abeta in the treatment method herein, such as the day of screening the subject before treatment is commenced).
- a therapy other than anti-Abeta at "baseline” i.e., at a set point in time before the administration of a first dose of anti-Abeta in the treatment method herein, such as the day of screening the subject before treatment is commenced.
- Such "naive" subjects are generally considered to be candidates for treatment with such additional drug(s).
- lifetime of a subject refers to the remainder of the life of the subject after starting treatment.
- the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigen. Furthermore, in contrast to polyclonal antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.
- the monoclonal antibodies herein specifically include “chimeric” antibodies in which a portion of the heavy and/or light chain is identical with or homologous to
- the "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain.
- the heavy chain constant domains that correspond to the different classes of immunoglobulins are called ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
- humanized forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin.
- humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity.
- donor antibody such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity.
- framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.
- humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance.
- the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human
- immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin lo sequence.
- the humanized antibody optionally will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
- Fc immunoglobulin constant region
- a "human antibody” is one which comprises an amino acid sequence
- Such techniques include, but are not limited to, screening human-derived combinatorial libraries, such as phage display libraries (see, e.g., Marks et al., J. Mol.
- an "isolated" antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes.
- an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic ⁇ e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic ⁇ e.g., ion exchange or reverse phase HPLC).
- electrophoretic e.g., SDS-PAGE
- IEF isoelectric focusing
- capillary electrophoresis capillary electrophoresis
- chromatographic ⁇ e.g., ion exchange or reverse phase HPLC e.g., ion exchange or reverse phase HPLC
- variable region refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen.
- the variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs).
- FRs conserved framework regions
- HVRs hypervariable regions
- VH or VL domain may be sufficient to confer antigen-binding specificity.
- antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al, J. Immunol. 150:880-887 (1993); Clarkson et al, Nature 352:624-628 (1991).
- hypervariable region when used herein refers to the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops.
- antibodies comprise six hypervariable regions; three in the VH (HI, H2, H3), and three in the VL (LI, L2, L3).
- a number of hypervariable region delineations are in use and are encompassed herein.
- CDRs Determining Regions
- Chothia refers instead to the location of the structural loops (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).
- the AbM hypervariable regions represent a compromise between the Kabat CDRs and Chothia structural loops, and are used by Oxford Molecular's AbM antibody modeling software.
- the "contact" hypervariable regions are based on an analysis of the available complex crystal structures. The residues from each of these HVRs are noted below.
- Hypervariable regions may comprise "extended hypervariable regions” as follows: 24-36 or 24-34 (LI), 46-56 or 49-56 or 50-56 or 52-56 (L2) and 89-97 (L3) in the VL and 26- 35 (HI), 50-65 or 49-65 (H2) and 93-102, 94-102 or 95-102 (H3) in the VH.
- the variable domain residues are numbered according to Kabat et ah, supra for each of these definitions.
- FR Framework residues
- the FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2- H2(L2)-FR3-H3(L3)-FR4.
- An "acceptor human framework” for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below.
- An acceptor human framework "derived from” a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less.
- the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.
- a "human consensus framework” is a framework which represents the most commonly occurring amino acid residue in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al. Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols. 1-3. et al.et al.
- Amyloid-Related Imaging Abnormality - Edema or "ARIA-E” encompasses cerebral vasogenic edema and sulcal effusion.
- Amyloid-Related Imaging Abnormality - Hemorrhage or "ARIA-H” encompasses microhemorrhage and superficial siderosis of the central nervous system.
- Apolipoprotein E4 carrier or "ApoE4 carrier,” used interchangeably herein with “apolipoprotein E4 positive” or “ApoE4 positive,” refers to an individual having at least one apolipoprotein E4 (or "ApoE4") allele. An individual with zero ApoE4 alleles is referred to herein as being “ApoE4 negative” or an "ApoE4 non-carrier.” See also Prekumar, et al., 1996, Am. J Pathol. 148:2083-95.
- Cerebral vasogenic edema refers to an excess accumulation of intravascular fluid or protein in the intracellular or extracellular spaces of the brain. Cerebral vasogenic edema is detectable by, e.g. , brain MRI, including, but not limited to FLAIR MRI, and can be asymptomatic ("asymptomatic vasogenic edema") or associated with neurological symptoms, such as confusion, dizziness, vomiting, and lethargy (“symptomatic vasogenic edema”) ⁇ see Sperling et al. Alzheimer's & Dementia, 7:367, 2011).
- Cerebral macrohemorrhage refers to an intracranial hemorrhage, or bleeding in the brain, of an area that is more than about 1 cm in diameter. Cerebral macrohemorrhage is detectable by, e.g., brain MRI, including but not limited to T2* -weighted GRE MRI, and can be asymptomatic ("asymptomatic macrohemorrhage") or associated with symptoms such as transient or permanent focal motor or sensory impairment, ataxia, aphasia, and dysarthria ("symptomatic macrohemorrhage”) (see, e.g., Chalela JA, Gomes J. Expert Rev. Neurother. 2004 4:267, 2004 and Sperling et al. Alzheimer's & Dementia, 7:367, 2011).
- asymptomatic macrohemorrhage e.g., Chalela JA, Gomes J. Expert Rev. Neurother. 2004 4:267, 2004 and Sperling et al.
- Cerebral microhemorrhage refers to an intracranial hemorrhage, or bleeding in the brain, of an area that is less than about 1 cm in diameter. Cerebral
- microhemorrhage is detectable by, e.g., brain MRI, including, but not limited to T2*- weighted GRE MRI, and can be asymptomatic ("asymptomatic microhemorrhage") or can potentially be associated with symptoms such as transient or permanent focal motor or sensory impairment, ataxia, aphasia, and dysarthria ("symptomatic microhemorrhage"). See, e.g., Greenberg, et ah, 2009, Lancet Neurol. 8: 165-74.
- sulcal effusion refers to an effusion of fluid in the furrows, or sulci, of the brain. Sulcal effusions are detectable by, e.g. , brain MRI, including but not limited to FLAIR MRI. Seesperling et al. Alzheimer's & Dementia, 7:367, 2011.
- the term "superficial siderosis of the central nervous system” refers to bleeding or hemorrhage into the subarachnoid space of the brain and is detectable by, e.g., brain MRI, including but not limited to T2* -weighted GRE MRI. Symptoms indicative of superficial siderosis of the central nervous system include sensorineural deafness, cerebellar ataxia, and pyramidal signs. See Kumara-N, Am J Neuroradiol. 31 :5, 2010.
- progression refers to the worsening of a disease over time.
- the "progression rate” or “rate of progression” of a disease refers to how fast or slow a disease develops over time in a patient diagnosed with the disease.
- the progression rate of a disease can be represented by measurable changes over time of particular characteristics of the disease.
- a patient carrying particular genetic trait is said to have, or more likely to have, "increased progression rate” if her disease state progresses faster than those patients without such genetic trait.
- a patient responding to a therapy is said to have, or more likely to have, "decreased progression rate” if her disease progression slows down after the therapy, when compared to her disease state prior to the treatment or to other patients without the treatment.
- “More likely to respond” as used herein refers to patients that are most likely to demonstrate a slowing down or prevention of progression of amyloidosis, e.g., AD. With regard to AD, “more likely to respond” refers to patients that are most likely to demonstrate a reduction in loss of function or cognition with treatment.
- the phrase "responsive to" in the context of the present invention indicates that a patient suffering from, being suspected to suffer or being prone to suffer from, or diagnosed with a disorder as described herein, shows a response to anti-Abeta treatment.
- the phrase "selecting a patient” or "identifying a patient” as used herein refers to using the information or data generated relating to the presence of an allele in a sample of a patient to identify or select the patient as more likely to benefit to benefit from a treatment comprising anti-Abeta antibody.
- the information or data used or generated may be in any form, written, oral or electronic.
- using the information or data generated includes communicating, presenting, reporting, storing, sending, transferring, supplying, transmitting, dispensing, or combinations thereof.
- communicating, presenting, reporting, storing, sending, transferring, supplying, transmitting, dispensing, or combinations thereof are performed by a computing device, analyzer unit or combination thereof.
- communicating, presenting, reporting, storing, sending, transferring, supplying, transmitting, dispensing, or combinations thereof are performed by a laboratory or medical professional.
- the information or data includes an indication that a specific allele is present or absent in the sample.
- the information or data includes an indication that the patient is more likely to respond to a therapy comprising anti-Abeta.
- Antibody effector functions refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype.
- Examples of antibody effector functions include: Clq binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation. It is known in the art that wild-type IgG4 antibodies have less effector function than wild-type IgGl antibodies.
- Fc region herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region.
- the term includes native sequence Fc regions and variant Fc regions.
- a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain.
- the C-terminal lysine (Lys447) of the Fc region may or may not be present.
- EU numbering system also called the EU index, as described in Kabat et al.et ah, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
- full length antibody “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
- Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages.
- Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.
- an “immunoconjugate” is an antibody conjugated to one or more heterologous molecule(s), including but not limited to a further therapeutic agent.
- An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment.
- An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
- isolated nucleic acid encoding an anti-Abeta antibody refers to one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a host cell.
- earsly Alzheimer's Disease or "early AD” as used herein (e.g., a "patient diagnosed with early AD” or a “patient suffering from early AD”) includes patients with mild cognitive impairement, such as a memory deficit, due to AD and patients having AD biomarkers, for example amyloid positive patients.
- micromild Alzheimer's Disease or "mild AD” as used herein (e.g., a “patient diagnosed with mild AD”) refers to a stage of AD characterized by an MMSE score of 20 to 26.
- Mild to moderate Alzheimer's Disease or “mild to moderate AD” as used herein encompasses both mild and moderate AD, and is characterized by an MMSE score of 18 to 26.
- moderate Alzheimer's Disease or “moderate AD” as used herein (e.g., a “patient diagnosed with moderate AD”) refers to a stage of AD characterized by an MMSE score of 18 to 19.
- naked antibody refers to an antibody that is not conjugated to a heterologous moiety (e.g., a further therapeuticmoiety) or radiolabel.
- the naked antibody may be present in a pharmaceutical formulation.
- Native antibodies refer to naturally occurring immunoglobulin molecules with varying structures.
- native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CHI, CH2, and CH3).
- VH variable region
- VL variable region
- the light chain of an antibody may be assigned to one of two types, called kappa ( ⁇ ) and lambda ( ⁇ ), based on the amino acid sequence of its constant domain.
- package insert is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.
- packetage insert is also used to refer to instructions customarily included in commercial packages of diagnostic products that contain information about the intended use, test principle, preparation and handling of reagents, specimen collection and preparation, calibration of the assay and the assay procedure, performance and precision data such as sensitivity and specificity of the assay.
- Percent (%) amino acid sequence identity with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
- % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2.
- the ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087.
- the ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code.
- the ALIGN-2 program should be compiled for use on a UNLX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
- % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows:
- composition refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
- a “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject.
- pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
- vector refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked.
- the term includes the vector as a self- replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced.
- Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors.”
- imaging agent is a compound that has one or more properties that permit its presence and/or location to be detected directly or indirectly.
- imaging agents include proteins and small molecule compounds incorporating a labeled moiety that permits detection.
- a "label” is a marker coupled with a molecule to be used for detection or imaging.
- labels include: a radiolabel, a fluorophore, a chromophore, or an affinity tag.
- the label is a radiolabel used for medical imaging, for example tc99m or 1123, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, mri), such as iodine-123 again, iodine-131, indium- 111, fluorine- 19, carbon-13, nitrogen- 15, oxygen- 17, gadolinium, manganese, iron, etc.
- NMR nuclear magnetic resonance
- the invention is based, in part, on improved methods of treatment.
- antibodies that bind to Abeta are provided.
- Antibodies of the invention are useful, e.g., for the diagnosis or treatment of Alzheimer's Disease ("AD”) and other diseases.
- AD Alzheimer's Disease
- the invention provides isolated antibodies that bind to Abeta.
- the invention provides an anti-Abeta antibody that can bind to monomeric, oligomeric and fibril forms of human Abeta with good affinity.
- the anti-Abeta antibody is an antibody that binds to an epitope of Abeta within residues 13-24 of Abeta. In one such embodiment, the antibody is crenezumab.
- the antibody comprises the heavy chain amino acid sequence set forth in SEQ ID NO: 5 and the light chain amino acid sequence set forth in SEQ ID NO:9. In another embodiment, the antibody comprises the heavy chain variable region of amino acids 1 to 112 of the amino acid sequence set forth in SEQ ID NO: 5 and the light chain variable region of amino acids 1 to 112 of the amino acid sequence set forth in SEQ ID NO:9. In another embodiment, the antibody comprises the HVR sequences of SEQ ID NO: 5 and SEQ ID NO:9. In another embodiment, the antibody comprises HVR sequences that are 95%, 96%, 97%, 98%, or 99% or more identical to the HVR sequences of SEQ ID NO:5 and SEQ ID NO:9.
- an anti-Abeta antibody is humanized.
- an anti-Abeta antibody comprises HVRs as in any of the above embodiments, and further comprises an acceptor human framework, e.g. a human immunoglobulin framework or a human consensus framework.
- an anti-Abeta antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%), or 100%) sequence identity to amino acids 1 to 112 of the amino acid sequence of SEQ ID NO:5.
- VH heavy chain variable domain
- a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-Abeta antibody comprising that sequence retains the ability to bind to Abeta.
- the anti-Abeta antibody comprises the VH sequence in SEQ ID NO:5, including post-translational modifications of that sequence.
- an anti-Abeta antibody comprising a light chain variable domain (VL) having at least 90%>, 91 >, 92%, 93%>, 94%>, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to amino acids 1 to 112 of the amino acid sequence of SEQ ID NO:9.
- VL light chain variable domain
- a VL sequence having at least 90%>, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-Abeta antibody comprising that sequence retains the ability to bind to Abeta.
- the anti-Abeta antibody comprises the VL sequence in SEQ ID NO:9, including post-translational modifications of that sequence.
- an anti-Abeta antibody comprising a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above.
- the invention provides an antibody that binds to the same epitope as an anti-Abeta antibody provided herein.
- an antibody is provided that binds to the same epitope as an anti-Abeta antibody comprising a VH sequence in SEQ ID NO:5 and a VL sequence in SEQ ID NO:9.
- an anti-Abeta antibody is a monoclonal antibody, including a chimeric, humanized or human antibody.
- an anti-Abeta antibody is an antibody fragment, e.g. , a Fv, Fab, Fab', scFv, diabody, or F(ab')2 fragment.
- the antibody is a full length antibody, e.g., an intact IgG4 antibody or other antibody class or isotype as defined herein.
- the antibody is a bispecific antibody.
- an anti-Abeta antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in Sections 1-7 below.
- the anti-Abeta antibody comprises a HVR-L1 comprising amino acid sequence SEQ ID NO:6; an HVR-L2 comprising amino acid sequence SEQ ID NO:7; an HVR-L3 comprising amino acid sequence SEQ ID NO: 8; an HVR-Hl comprising amino acid sequence SEQ ID NO:2; an HVR-H2 comprising amino acid sequence SEQ ID NO: 3; and an HVR-H3 comprising amino acid sequence SEQ ID NO: 4.
- the antibody comprises the heavy and light sequences SEQ ID NO:5 and SEQ ID NO:9.
- the antibody comprises the variable region sequences in SEQ ID NO:5 and SEQ ID NO:9.
- an anti-Abeta antibody can be humanized.
- an anti-Abeta antibody comprises HVRs as in any of the above
- an acceptor human framework e.g. a human
- immunoglobulin framework or a human consensus framework.
- an antibody provided herein has a dissociation constant (Kd) of ⁇ ⁇ , ⁇ 100 nM, ⁇ 10 nM, ⁇ 1 nM, ⁇ 0.1 nM, ⁇ 0.01 nM, or ⁇ 0.001 nM (e.g. 10 ⁇ 8 M or less, e.g. from 10 ⁇ 8 M to 10 "13 M, e.g., from 10 "9 M to 10 "13 M).
- Kd dissociation constant
- Kd is measured by a radiolabeled antigen binding assay (RIA) performed with the Fab version of an antibody of interest and its antigen as described by the following assay.
- RIA radiolabeled antigen binding assay
- MICROTITER® multi-well plates (Thermo Scientific) are coated overnight with 5 ⁇ g/ml of a capturing anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), and subsequently blocked with 2% (w/v) bovine serum albumin in PBS for two to five hours at room temperature (approximately 23°C).
- a non-adsorbent plate (Nunc #269620)
- 100 pM or 26 pM [125I]-antigen are mixed with serial dilutions of a Fab of interest (e.g., consistent with assessment of the anti-VEGF antibody, Fab-12, in Presta et al, Cancer Res.
- the Fab of interest is then incubated overnight; however, the incubation may continue for a longer period (e.g. , about 65 hours) to ensure that equilibrium is reached. Thereafter, the mixtures are transferred to the capture plate for incubation at room temperature (e.g., for one hour). The solution is then removed and the plate washed eight times with 0.1% polysorbate 20 (TWEEN-20®) in PBS. When the plates have dried, 150 ⁇ /well of scintillant (MICROSCINT-20 TM; Packard) is added, and the plates are counted on a TOPCOUNT TM gamma counter (Packard) for ten minutes. Concentrations of each Fab that give less than or equal to 20% of maximal binding are chosen for use in competitive binding assays.
- Kd is measured using surface plasmon resonance assays using a BIACORE®-2000 or a BIACORE ®-3000 (BIAcore, Inc.,
- CM5 chips Piscataway, NJ
- immobilized antigen CM5 chips at 25°C with immobilized antigen CM5 chips at ⁇ 10 response units (RU).
- carboxymethylated dextran biosensor chips CM5, BIACORE, Inc.
- EDC N-ethyl-N'- (3-dimethylaminopropyl)-carbodiimide hydrochloride
- NHS N- hydroxysuccinimide
- Antigen is diluted with 10 mM sodium acetate, pH 4.8, to 5 ⁇ g/ml (-0.2 ⁇ ) before injection at a flow rate of 5 ⁇ /minute to achieve approximately 10 response units (RU) of coupled protein.
- an antibody provided herein is an antibody fragment.
- Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv, and scFv fragments, and other fragments described below.
- Fab fragment antigen
- Fab' fragment antigen binding domain
- Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific. See, for example, EP 404,097; WO 1993/01161; Hudson et al, Nat. Med. 9: 129-134 (2003); and Hollinger et al, Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al, Nat. Med. 9: 129-134 (2003).
- Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody.
- a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No. 6,248,516 Bl).
- two or more single-domain antibodies may be joined together to form an immunoglobulin construct with multivalent affinity ⁇ i.e., the N- or C-terminus of a first single-domain antibody may be fused or otherwise joined to the N- or C-terminus of a second single-domain antibody).
- Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells ⁇ e.g. E. coli or phage), as described herein. 3. Chimeric and Humanized Antibodies
- an antibody provided herein is a chimeric antibody.
- chimeric antibodies are described, e.g., in U.S. Patent No. 4,816,567; and Morrison et al, Proc. Natl. Acad. Sci. USA, 81 :6851-6855 (1984)).
- a chimeric antibody comprises a non-human variable region ⁇ e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region.
- a chimeric antibody is a "class switched" antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.
- a chimeric antibody is a humanized antibody.
- a non-human antibody is humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody.
- a humanized antibody comprises one or more variable domains in which HVRs, e.g., CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences.
- a humanized antibody optionally will also comprise at least a portion of a human constant region.
- some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody ⁇ e.g. , the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.
- Human framework regions that may be used for humanization include but are not limited to: framework regions selected using the "best-fit" method (see, e.g., Sims .et al. J. Immunol. 151 :2296 (1993)); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g. , Carter et al. Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al. J. Immunol, 151 :2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci.
- an antibody provided herein is a human antibody.
- Human antibodies can be produced using various techniques known in the art. Human antibodies are described generally in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).
- Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge.
- Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or which are present extrachromosomally or integrated randomly into the animal's chromosomes.
- the endogenous immunoglobulin loci have generally been inactivated.
- Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, e.g., Kozbor J. Immunol, 133: 3001 (1984); Brodeur et al, Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al, J. Immunol, 147: 86 (1991).) Human antibodies generated via human B-cell hybridoma technology are also described in Li et al, Proc. Natl. Acad. Sci. USA, 103:3557-3562 (2006).
- Additional methods include those described, for example, in U.S. Patent No. 7,189,826 (describing production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26(4):265-268 (2006) (describing human-human hybridomas).
- Human hybridoma technology Trioma technology
- Vollmers and Brandlein, Histology and Histopathology, 20(3):927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27(3): 185-91 (2005).
- Human antibodies may also be generated by isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences may then be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries are described below.
- Antibodies of the invention may be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics. Such methods are reviewed, e.g., in Hoogenboom et al. in Methods in Molecular Biology 178: 1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001) and further described, e.g., in the McCafferty et al., Nature
- naive repertoire can be cloned ⁇ e.g., from human) to provide a single source of antibodies to a wide range of non-self and also self antigens without any immunization as described by Griffiths et al., EMBO J, 12: 725-734 (1993).
- naive libraries can also be made synthetically by cloning unrearranged V-gene segments from stem cells, and using PCR primers containing random sequence to encode the highly variable CDR3 regions and to accomplish rearrangement in vitro, as described by Hoogenboom and Winter, J. Mol. Biol., 227: 381-388 (1992).
- Patent publications describing human antibody phage libraries include, for example: US Patent No. 5,750,373, and US Patent Publication Nos. 2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598,
- Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.
- an antibody provided herein is a multispecific antibody, e.g. a bispecific antibody.
- Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites.
- one of the binding specificities is for Abeta and the other is for any other antigen.
- bispecific antibodies may bind to two different epitopes of Abeta. Bispecific antibodies may also be used to localize cytotoxic agents to cells. Bispecific antibodies can be prepared as full length antibodies or antibody fragments.
- Multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (see Milstein and Cuello, Nature 305: 537 (1983)), WO 93/08829, and Traunecker et al, EMBO J. 10: 3655 (1991)), and "knob-in-hole” engineering (see, e.g., U.S. Patent No. 5,731,168).
- Multi-specific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO
- Engineered antibodies with three or more functional antigen binding sites are also included herein (see, e.g. US 2006/0025576A1).
- the antibody or fragment herein also includes a "Dual Acting FAb” or “DAF” comprising an antigen binding site that binds to Abeta as well as another, different antigen (see, US 2008/0069820, for example). 7. Antibody Variants
- amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody.
- Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding.
- antibody variants having one or more amino acid substitutions are provided.
- Sites of interest for substitutional mutagenesis include the HVRs and FRs.
- Conservative substitutions are shown in Table 1 under the heading of "conservative substitutions.” More substantial changes are provided in Table 1 under the heading of "exemplary substitutions,” and as further described below in reference to amino acid side chain classes.
- Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, or improved ADCC or CDC.
- Amino acids may be grouped according to common side-chain properties:
- Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
- substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g. a humanized or human antibody).
- a parent antibody e.g. a humanized or human antibody
- modifications e.g., improvements
- an exemplary substitutional variant is an affinity matured antibody.
- affinity matured antibodies will have nanomolar or even picomolar affinities for the target antigen.
- Affinity matured antibodies are produced by procedures known in the art, including, e.g., using phage display-based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated and the variant antibodies displayed on phage and screened for a particular biological activity (e.g. binding affinity).
- HVRs may be made in HVRs, e.g. , to improve antibody affinity.
- HVR "hotspots” i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, Methods Mol. Biol. 207:179-196 (2008)), and/or SDRs (a-CDRs), with the resulting variant VH or VL being tested for binding affinity.
- Affinity maturation by constructing and reselecting from secondary libraries has been described, e.g., in Hoogenboom et al.
- affinity maturation diversity is introduced into the variable genes chosen for maturation by any of a variety of methods ⁇ e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis).
- a secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity.
- Another method to introduce diversity involves HVR-directed approaches, in which several HVR residues ⁇ e.g., 4-6 residues at a time) are randomized.
- HVR residues involved in antigen binding may be specifically identified, e.g., using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted.
- substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antibody to bind antigen.
- conservative alterations ⁇ e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in HVRs.
- Such alterations may be outside of HVR "hotspots" or SDRs.
- each HVR either is unaltered, or contains no more than one, two or three amino acid substitutions.
- a useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells (1989) Science, 244:1081-1085.
- a residue or group of target residues ⁇ e.g., charged residues such as arg, asp, his, lys, and glu
- a neutral or negatively charged amino acid ⁇ e.g., alanine or polyalanine
- a crystal structure of an antigen-antibody complex to identify contact points between the antibody and antigen.
- Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution.
- Variants may be screened to determine whether they contain the desired properties.
- Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
- terminal insertions include an antibody with an N-terminal methionyl residue.
- Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g. for ADEPT) or a polypeptide which increases the serum half-life of the antibody.
- an antibody provided herein is altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of
- glycosylation sites to an antibody may be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites is created or removed.
- the carbohydrate attached thereto may be altered.
- Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, e.g., Wright et al. TIBTECH 15:26-32 (1997).
- oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the "stem" of the biantennary oligosaccharide structure.
- modifications of the oligosaccharide in an antibody of the invention may be made in order to create antibody variants with certain improved properties.
- antibody variants having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region.
- the amount of fucose in such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65%> or from 20% to 40%.
- the amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297, relative to the sum of all glycostructures attached to Asn 297 (e. g. complex, hybrid and high mannose structures) as measured by MALDI-TOF mass spectrometry, as described in WO 2008/077546, for example.
- Asn297 refers to the asparagine residue located at about position 297 in the Fc region (Eu numbering of Fc region residues); however, Asn297 may also be located about ⁇ 3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in antibodies.
- Such fucosylation variants may have improved ADCC function. See, e.g., US Patent Publication Nos. US 2003/0157108 (Presta, L.); US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd). Examples of publications related to "defucosylated” or "fucose-deficient" antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US
- Examples of cell lines capable of producing defucosylated antibodies include Lecl3 CHO cells deficient in protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249:533-545 (1986); US Pat Appl No US 2003/0157108 Al, Presta, L; and WO 2004/056312 Al, Adams et al, especially at Example 11), and knockout cell lines, such as alpha- 1 ,6-fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004); Kanda, Y. et al, Biotechnol. Bioeng., 94(4):680-688 (2006); and WO2003/085107).
- Antibodies variants are further provided with bisected oligosaccharides, e.g. , in which a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and/or improved ADCC function. Examples of such antibody variants are described, e.g., in WO 2003/011878 (Jean- Mairet et al); US Patent No. 6,602,684 (Umana et al); and US 2005/0123546 (Umana et al). Antibody variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided.
- Such antibody variants may have improved CDC function.
- Such antibody variants are described, e.g., in WO 1997/30087 (Patel et al.); WO 1998/58964 (Raju, S.); and WO 1999/22764 (Raju, S.).
- one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant.
- the Fc region variant may comprise a human Fc region sequence ⁇ e.g., a human IgGl, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification ⁇ e.g. a substitution) at one or more amino acid positions.
- the invention contemplates an antibody variant that possesses some but not all effector functions, which make it a desirable candidate for applications in which the half life of the antibody in vivo is important yet certain effector functions (such as complement and ADCC) are unnecessary or deleterious.
- In vitro and/or in vivo cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities.
- Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks FcyR binding (hence likely lacking ADCC activity), but retains FcRn binding ability.
- NK cells express Fc RIII only, whereas monocytes express Fc ⁇ RI, Fc ⁇ RII and Fc RIII.
- FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991).
- Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest is described in U.S. Patent No. 5,500,362 (see, e.g. Hellstrom, I. et al. Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I et al, Proc. Nat'l Acad.
- non-radioactive assays methods may be employed (see, for example, ACTITM non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, CA; and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, WI).
- Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells.
- ADCC activity of the molecule of interest may be assessed in vivo, e.g., in a animal model such as that disclosed in Clynes et al. Proc. Nat'l Acad. Sci. USA 95:652-656 (1998).
- Clq binding assays may also be carried out to confirm that the antibody is unable to bind Clq and hence lacks CDC activity. See, e.g., Clq and C3c binding ELISA in WO 2006/029879 and WO 2005/100402.
- a CDC assay may be performed (see, for example, Gazzano-Santoro et al, J. Immunol. Methods 202: 163 (1996); Cragg, M.S.
- FcRn binding and in vivo clearance/half life determinations can also be performed using methods known in the art (see, e.g., Petkova, S.B. et al, Int'l. Immunol. 18(12): 1759-1769 (2006)).
- Antibodies with reduced effector function include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Patent No. 6,737,056).
- Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called "DANA" Fc mutant with substitution of residues 265 and 297 to alanine (US Patent No. 7,332,581).
- Certain antibody variants with improved or diminished binding to FcRs are described. (See, e.g., U.S. Patent No. 6,737,056; WO 2004/056312, and Shields et al, J. Biol. Chem. 9(2): 6591-6604 (2001).)
- an antibody variant comprises an Fc region with one or more amino acid substitutions which improve ADCC, e.g., substitutions at positions 298, 333, and/or 334 of the Fc region (EU numbering of residues).
- alterations are made in the Fc region that result in altered (i.e., either improved or diminished) Clq binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as described in US Patent No. 6,194,551, WO 99/51642, and ldusogie et al. J. Immunol. 164: 4178-4184 (2000).
- CDC Complement Dependent Cytotoxicity
- Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (US Patent No. 7,371,826). See also Duncan & Winter, Nature 322:738- 40 (1988); U.S. Patent No. 5,648,260; U.S. Patent No. 5,624,821; and WO 94/29351 concerning other examples of Fc region variants.
- cysteine engineered antibodies e.g., "thioMAbs”
- one or more residues of an antibody are substituted with cysteine residues.
- the substituted residues occur at accessible sites of the antibody.
- reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create an immunoconjugate, as described further herein.
- any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; Al 18 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region.
- Cysteine engineered antibodies may be generated as described, e.g., in U.S. Patent No.
- an antibody provided herein may be further modified to contain additional nonproteinaceous moieties that are known in the art and readily available.
- the moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers.
- Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol,
- carboxymethylcellulose dextran
- polyvinyl alcohol polyvinyl pyrrolidone
- poly-1, 3-dioxolane poly-l,3,6-trioxane
- ethylene/maleic anhydride copolymer polyaminoacids (either
- polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water.
- the polymer may be of any molecular weight, and may be branched or unbranched.
- the number of polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.
- conjugates of an antibody and nonproteinaceous moiety that may be selectively heated by exposure to radiation are provided.
- the nonproteinaceous moiety is a carbon nanotube (Kam et al, Proc. Natl. Acad. Sci. USA 102: 11600-11605 (2005)).
- the radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the nonproteinaceous moiety to a temperature at which cells proximal to the antibody-nonproteinaceous moiety are killed.
- Antibodies may be produced using recombinant methods and compositions, e.g. , as described in U.S. Patent No. 4,816,567.
- isolated nucleic acid encoding an anti-Abeta antibody described herein is provided.
- Such nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chains of the antibody).
- one or more vectors e.g., expression vectors
- a host cell comprising such nucleic acid is provided.
- a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody.
- the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NSO, Sp20 cell).
- a method of making an anti-Abeta antibody comprises culturing a host cell comprising a nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).
- nucleic acid encoding an antibody is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell.
- nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).
- Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein.
- antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed.
- expression of antibody fragments and polypeptides in bacteria see, e.g., U.S. Patent Nos.
- the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.
- eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been "humanized,” resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li et al, Nat. Biotech. 24:210-215 (2006).
- Suitable host cells for the expression of glycosylated antibody are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells. [0260] Plant cell cultures can also be utilized as hosts. See, e.g., US Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIESTM technology for producing antibodies in transgenic plants).
- Vertebrate cells may also be used as hosts.
- mammalian cell lines that are adapted to grow in suspension may be useful.
- useful mammalian host cell lines are monkey kidney CVl line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse Sertoli cells (TM4 cells as described, e.g., in Mather, Biol. Reprod.
- monkey kidney cells (CVl); African green monkey kidney cells (VEPvO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3 A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al, Annals N.Y. Acad. Sci. 383:44-68 (1982); MRC 5 cells; and FS4 cells.
- Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR- CHO cells (Urlaub et al., Proc. Natl. Acad. Sci.
- Anti-Abeta antibodies provided herein may be identified, screened for, or characterized for their physical/chemical properties and/or biological activities by various assays known in the art.
- an antibody of the invention is tested for its antigen binding activity, e.g., by known methods such as ELISA, Western blot, etc.
- competition assays may be used to identify an antibody that competes with an anti-Abeta antibody of the invention for binding to Abeta.
- a competing antibody binds to the same epitope ⁇ e.g., a linear or a conformational epitope) that is bound by crenezumab or another anti-Abeta antibody specified herein.
- Detailed exemplary methods for mapping an epitope to which an antibody binds are provided in Morris (1996) "Epitope Mapping Protocols," in Methods in Molecular Biology vol. 66 (Humana Press, Totowa, NJ).
- immobilized Abeta in the desired form e.g.
- monomeric, oligomeric, or fibril is incubated in a solution comprising a first labeled antibody that binds to Abeta (e.g., crenezumab) and a second unlabeled antibody that is being tested for its ability to compete with the first antibody for binding to Abeta.
- Abeta e.g., crenezumab
- the second antibody may be present in a hybridoma supernatant.
- immobilized Abeta is incubated in a solution comprising the first labeled antibody but not the second unlabeled antibody. After incubation under conditions permissive for binding of the first antibody to Abeta, excess unbound antibody is removed, and the amount of label associated with immobilized Abeta is measured.
- assays are provided for identifying anti- Abeta antibodies thereof having biological activity, for example the biological activity of crenezumab.
- Biological activity may include, but is not limited to, e.g., prevention of aggregation of monomeric Abeta into oligomeric Abeta, or disaggregation of oligomeric Abeta into monomeric Abeta.
- Antibodies having such biological activity in vivo and/or in vitro are also provided.
- an antibody of the invention is tested for such biological activity.
- the present disclosure is based on the discovery that a polymorphism in a gene, CLUSTERIN (also known as Apolipoprotein J or ApoJ, GenPept accession no. NP 001822), correlates with efficacy of anti- Abeta antibody treatment (e.g. , an anti- Abeta antibody or antigen-binding fragment thereof).
- CLUSTERIN also known as Apolipoprotein J or ApoJ, GenPept accession no. NP 001822
- the presence of a T nucleotide at SNP rs 1532278, a SNP in the CLUSTERIN gene is associated with favorable outcomes in patients with mild-to-moderate AD, and particular subpopulations thereof. Consequently, the present disclosure provides methods and tools, including but not limited to methods and tools for identifying and selecting patients likely to benefit from or respond to treatment for AD comprising an anti- Abeta antibody.
- the present disclosure provides a method of selecting a patient for treatment with an anti- Abeta antibody, wherein the patient suffers from early or mild to moderate AD.
- the method comprises detecting the presence or absence of a CLUSTERIN allele, in particular the presence of a CLUSTERIN allele having a T nucleotide at SNP rs 1532278 or an equivalent allele thereof, in a sample from the patient.
- the method further comprises selecting a patient in which a CLUSTERIN allele having a T nucleotide at SNP rs 1532278 or an equivalent allele thereof is detected as more likely to respond to treatment with an anti-Abeta antibody.
- the present disclosure provides a method of predicting whether an individual suffering from early or mild to moderate AD is likely to respond to treatment for AD comprising an anti-Abeta antibody.
- the method comprises determining the identity of a nucleotide at SNP rs 1532278 in a sample from the individual, wherein an individual having a T nucleotide at SNP rs 1532278 has an increased likelihood of responding to treatment comprising an anti-Abeta antibody.
- the method comprises detecting the presence or absence of a CLUSTERIN allele, in particular the presence of a CLUSTERIN allele having a T nucleotide at SNP rs 1532278 or an equivalent allele thereof, in a sample from the patient.
- the present disclosure provides a method of optimizing therapeutic efficacy of treatment for AD, comprising determining the genotype of a patient, wherein a patient who is determined to carry at least one CLUSTERIN allele, in particular the presence of a CLUSTERIN allele having a T nucleotide at SNP rs 1532278 or an equivalent allele thereof, is more likely to respond to treatment with an anti-Abeta antibody.
- the present disclosure provides a method for determining the likelihood that a patient suffering from AD will benefit from treatment for AD comprising an anti-Abeta antibody.
- a therapy comprising an anti-Abeta antibody (e.g., crenezumab, or antigen-binding fragment thereof).
- a sample can be obtained from a patient, and examined by various in vitro assays to determine the presence or absence of an allele associated with treatment effect in patients suffering from AD who have been treated with an anti-Abeta antibody. Suitable samples are described herein, infra, and can be from blood, saliva, cheek swab, body tissue or from a bodily fluid.
- Presence of a biomarker or SNP can be determined based on any suitable criterion known in the art, including but not limited to mRNA, cDNA, proteins, protein fragments and/or gene copy number.
- the CLUSTERIN allele is the rsl532278:T allele, or equivalent allele thereof, or comprises a T at the SNP rsl532278.
- Alternate SNPs, in linkage disequilibrium to rs 1532278 can also be used in the methods of the present disclosure.
- the linkage disequilibrium is a D' measure or an r measure.
- the D' measure between the selected SNP and the alternate SNP is > 0.60.
- the D' measure between the selected SNP and the alternate SNP is > 0.70, 0.80 or 0.90.
- the D' measure between the selected SNP and the alternate SNP is 1.0.
- the r measure between the selected SNP and the alternate SNP is > 0.60. In some embodiments the r measure between the selected SNP and the alternate SNP is > 0.70, 0.80 or 0.90. In some embodiments, the r measure between the selected SNP and the alternate SNP is 1.0. In some embodiments, the alternate SNP is located within 500,000 base pairs upstream or downstream of the selected SNP.
- Analysis of SNPs in a sample can be analyzed in blood, tissue or other bodily fluids by a number of methodologies, many of which are known in the art and understood by the skilled artisan, including but not limited to, DNA sequencing, RNA sequencing, polymerase chain reaction analysis of DNA, polymerase chain reaction analysis of RNA, oligonucleotide based hybridization, in situ hybridization, oligonucleotide based primer extension, electrophoresis and HPLC.
- Additional techniques for detecting SNPs include but are not limited to the following techniques: scanning probe and nanopore DNA sequencing, pyrosequencing, Denaturing Gradient Gel Electrophoresis (DGGE), Temporal Temperature Gradient Electrophoresis (TTGE), Zn(II)-cyclen polyacrylamide gel electrophoresis, homogeneous fluorescent PCR-based single nucleotide polymorphism analysis, phosphate- affinity polyacrylamide gel electrophoresis, high-throughput SNP genotyping platforms, molecular beacons, 5 'nuclease reaction, Taqman assay, MassArray (single base primer extension coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry), trityl mass tags, genotyping platforms (such as the Invader Assay®), single base primer extension (SBE) assays, PCR amplification (e.g.
- the presence of a SNP may also be inferred from analysis of protein based techniques (to examine, for example, levels of protein expression or function), including immunoassay (e.g. ELISA, ELIFA, immunohistochemical and/or Western blot analysis, immunoprecipitation, molecular binding assays, fluorescence activated cell sorting (FACS) and the like, quantitative blood based assays (as for example Serum ELISA) in situ hybridization, or functional assays including biochemical enzymatic activity assays or cell based systems, as well as any one of the wide variety of assays that can be performed by gene and/or tissue array analysis.
- immunoassay e.g. ELISA, ELIFA, immunohistochemical and/or Western blot analysis, immunoprecipitation, molecular binding assays, fluorescence activated cell sorting (FACS) and the like
- quantitative blood based assays as for example Serum ELISA
- functional assays including biochemical
- Multiplexed immunoassays such as those available from Rules Based Medicine, bead based immunoassays e.g. Luminex, ELISA or Meso Scale Discovery (MSD) may also be used.
- bead based immunoassays e.g. Luminex, ELISA or Meso Scale Discovery (MSD) may also be used.
- AS-PCR allele-specific PCR
- U.S. Patent No. 6,627,402. This technique detects mutations or polymorphisms in nucleic acid sequences in the presence of wild-type variants of the sequences.
- the desired variant of the target nucleic acid is amplified, while the other variants are not, at least not to a detectable level.
- One measure of discrimination of an allele-specific PCR is the difference between Ct values (ACt) in the amplification reactions involving the two alleles.
- Each amplification reaction is characterized by a "growth curve” or "amplification curve" in the context of a nucleic acid amplification assay is a graph of a function, where an independent variable is the number of amplification cycles and a dependent variable is an amplification-dependent measurable parameter measured at each cycle of amplification, such as fluorescence emitted by a fluorophore.
- the amplification-dependent measurable parameter is the amount of fluorescence emitted by the probe upon hybridization, or upon the hydrolysis of the probe by the nuclease activity of the nucleic acid polymerase, see Holland et al., (1991) Proc. Natl. Acad. Sci. 88:7276-7280 and U.S. Patent No. 5,210,015.
- a growth curve is characterized by a "threshold value" (or Ct value) which is a number of cycles where a predetermined magnitude of the measurable parameter is achieved.
- Ct value or Ct value
- At least one primer is allele-specific such that primer extension occurs only (or preferentially) when the specific variant of the sequence is present and does not occur (or occurs less efficiently, i.e. with a substantial ACt) when another variant is present.
- the discriminating nucleotide in the primer i.e. the nucleotide matching only one variant of the target sequence, is the 3 '-terminal nucleotide.
- the 3 ' terminus of the primer is only one of many determinants of specificity. For example, additional mismatches may also affect discrimination. See U.S. Patent Application Ser. No.
- Another approach is to include non-natural or modified nucleotides that alter base pairing between the primer and the target sequence (U.S. Patent No. 6,001,611, incorporated herein in its entirety by reference.)
- the reduced extension kinetics and thus specificity of a primer is influenced by many factors including overall sequence context of the mismatch and other nucleic acids present in the reaction. The effect of these external factors on each additional mismatch as well as of each additional non-natural nucleotide either alone or in combination cannot be predicted.
- the present disclosure provides oligonucleotides specific for determining polymorphism in CLUSTERIN, in particular oligonucleotides specific for rs 1532278 in CLUSTERIN.
- the presence of polymorphism is detected with a probe.
- the probe may be labeled with a radioactive, or a chromophore (fluorophore) label, e.g., a label incorporating FAM, JA270, CY5 family dyes, or HEX dyes.
- a chromophore label e.g., a label incorporating FAM, JA270, CY5 family dyes, or HEX dyes.
- the mutation may be detected by real-time polymerase chain reaction (rt-PCR), where hybridization of the probe results in enzymatic digestion of the probe and detection of the resulting fluorescence (TaqManTM probe method, Holland et al. (1991) P.N.A.S. USA 88:7276-7280).
- polymorphism and the amplification product may be detected by gel electrophoresis followed by staining or by blotting and hybridization as described e.g., in Sambrook, J. and Russell, D.W. (2001) Molecular Cloning, 3rd ed. CSHL Press, Chapters 5 and 9.
- a "fluorescent dye” or a “fluorophore” is a compound or a moiety attached for example, to a nucleic acid, which is capable of emitting light radiation when excited by a light of a suitable wavelength.
- Typical fluorescent dyes include rhodamine dyes, cyanine dyes, fluorescein dyes and BODIPY® dyes.
- a fluorophore is a fluorescent chromophore.
- FRET or “fluorescent resonance energy transfer” or “Foerster resonance energy transfer” is a transfer of energy between at least two chromophores, a donor chromophore and an acceptor chromophore (referred to as a quencher).
- the donor typically transfers the energy to the acceptor when the donor is excited by light radiation with a suitable wavelength.
- the acceptor When the acceptor is a "dark" quencher, it dissipates the transferred energy in a form other than light.
- Commonly used dark quenchers are BlackHole QuenchersTM (BHQ), Biosearch Technologies, Inc. (Novato, CaL), Iowa BlackTM, Integrated DNA Tech., Inc. (Coralville, Iowa), BlackBerryTM Quencher 650 (BBQ-650), Berry & Assoc., (Dexter, Mich.).
- donor-quencher pairs include the FAM-BHQ pair, the CY5-BHQ pair and the HEX-BHQ pair.
- a sample comprising a biomarker or SNP can be obtained by methods well known in the art. See under Definitions. In addition, the progress of therapy can be monitored more easily by testing such body samples for SNPs.
- Genotyping arrays may be used to analyze DNA or RNA to detect the presence of SNPs.
- Illumina based array technology which is a commercially available microarray system which comprises > 700K loci (Oliphant et al., Biotechniques, Supp: 56-8, 60-1 (2002)) and is a common method used for DNA and RNA analysis (e.g. identification of SNPs in nucleic acid samples).
- the Illumina microarray technology utilizes 3 -micron silica beads that self assemble in micro wells on either of two substrates: fiber optic bundles or planar silica slides. Each bead is covered with hundreds of thousands of copies of specific oligonucleotides that act as the capture sequences.
- Expression of a selected gene or biomarker in a tissue or cell sample may also be examined by way of functional or activity-based assays.
- the biomarker is an enzyme
- the SNP status of a patient based on the test results may be provided in a report.
- the report may be in any form of written materials (e.g., in paper or digital form, or on internet) or oral presentation(s) (e.g., either in person (live) or as recorded).
- the report may further indicates to a health professional (e.g., a physician) that the patient may benefit from or is likely to respond to anti-Abeta treatment.
- kits for detecting the presence of a polymorphism or determining the genotype of patient from a sample comprising a container, a label on said container, and a composition contained within said container; wherein the composition includes one or more primary antibodies that bind to one or more target polypeptide sequences corresponding to an autoantibody to a SNP, the label on the container indicating that the composition can be used to evaluate the presence of one or more target proteins in at least one type of mammalian cell, and instructions for using the antibodies for evaluating the presence of one or more target proteins in at least one type of mammalian cell.
- the kit can further comprise a set of instructions and materials for preparing a tissue sample and applying antibody and probe to the same section of a tissue sample.
- the kit may include both a primary and secondary antibody, wherein the secondary antibody is conjugated to a label, e.g., an enzymatic label.
- any of the anti-Abeta antibodies provided herein is useful for detecting the presence of Abeta in a biological sample.
- the term "detecting" as used herein encompasses quantitative or qualitative detection.
- a biological sample comprises a cell or tissue, such as serum, plasma, nasal swabs, sputum, cerebrospinal fluid, , aqueous humor of the eye and the like, or tissue or cell samples obtained from an organism such as samples containing neural or brain tissue.
- an anti-Abeta antibody for use in a method of diagnosis or detection is provided.
- a method of detecting the presence of Abeta in a biological sample is provided.
- the method comprises contacting the biological sample with an anti-Abeta antibody as described herein under conditions permissive for binding of the anti-Abeta antibody to Abeta, and detecting whether a complex is formed between the anti-Abeta antibody and Abeta.
- Such method may be an in vitro or in vivo method.
- Exemplary disorders that may be diagnosed using an antibody of the invention are diseases and disorders caused by or associated with amyloid or amyloid-like proteins. These include, but are not limited to, diseases and disorders caused by the presence or activity of amyloid-like proteins in monomeric, fibril, or polymeric state, or any combination of the three, including by amyloid plaques.
- Exemplary diseases include, but are not limited to, secondary amyloidosis and age-related amyloidosis, such as diseases including, but not limited to, neurological disorders such as Alzheimer's Disease (“AD"), diseases or conditions characterized by a loss of cognitive memory capacity such as, for example, mild cognitive impairment (MCI), Lewy body dementia, Down's syndrome, hereditary cerebral hemorrhage with amyloidosis (Dutch type), the Guam Parkinson-Demential complex and other diseases which are based on or associated with amyloid-like proteins such as progressive supranuclear palsy, multiple sclerosis, Creutzfeld Jacob disease, Parkinson's disease, HIV-related dementia, ALS (amyotropic lateral sclerosis), inclusion-body myositis (IBM), adult onset diabetes, endocrine tumor and senile cardiac amyloidosis, and various eye diseases including macular degeneration, drusen-related optic neuropathy, glaucoma, and cataract due to beta- amyloid deposition
- labeled anti-Abeta antibodies include, but are not limited to, labels or moieties that are detected directly (such as fluorescent, chromophoric, electron-dense, chemiluminescent, and radioactive labels), as well as moieties, such as enzymes or ligands, that are detected indirectly, e.g., through an enzymatic reaction or
- Exemplary labels include, but are not limited to, the radioisotopes P, 14 C, 125 1, 3 H, and 13 T, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luceriferases, e.g., firefly luciferase and bacterial luciferase (U.S. Patent No.
- luciferin 2,3-dihydrophthalazinediones
- horseradish peroxidase HRP
- alkaline phosphatase alkaline phosphatase
- ⁇ -galactosidase glucoamylase
- lysozyme saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase
- heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP
- HRP horseradish peroxidase
- lactoperoxidase or microperoxidase, biotin/avidin, spin labels, bacteriophage labels, stable free radicals, and the like.
- the present disclosure further provides for in vitro uses of an agent for detecting a polymorphism in a CLUSTERIN allele.
- an agent is provided for detecting a CLUSTERIN allele, for the identification of a patient having early, mild, or mild to moderate AD, who is likely to respond to treatment comprising an anti-Abeta antibody.
- the agent is capable of detected the presence of a CLUSTERIN allele having a T nucleotide in SNP rsl532278 or an equivalent allele thereof.
- compositions of an anti-Abeta antibody as described herein are prepared by mixing such antibody or molecule having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions.
- Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arg
- sHASEGP soluble neutral-active hyaluronidase glycoproteins
- rHuPH20 HYLENEX®, Baxter International, Inc.
- a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.
- an antibody of the invention may be formulated in an arginine buffer.
- the arginine buffer may be an arginine succinate buffer.
- the concentration of the arginine succinate buffer may be 50 mM or greater.
- the concentration of the arginine succinate buffer may be 100 mM or greater.
- the concentration of the arginine succinate buffer may be 150 mM or greater.
- the concentration of the arginine succinate buffer may be 200 mM or greater.
- the arginine buffer formulation may further contain a surfactant.
- the surfactant is a polysorbate.
- the polysorbate is polysorbate 20.
- the concentration of polysorbate 20 in the formulation is 0.1% or less.
- the concentration of polysorbate 20 in the formulation is 0.05% or less.
- the pH of the arginine buffer formulation is between 4.5 and 7.0.
- the pH of the arginine buffer formulation is between 5.0 and 6.5.
- the pH of the arginine buffer formulation is between 5.0 and 6.0.
- the pH of the arginine buffer formulation is 5.5.
- the antibody of the invention may be crenezumab.
- Aqueous antibody formulations include those described in US Patent No. 6,171,586 and WO2006/044908, the latter formulations including a histidine-acetate buffer.
- the formulation herein may also contain more than one active ingredients as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, it may be desirable to further provide one or more compounds to prevent or treat symptoms of Alzheimer's Disease. Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended.
- Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano- particles and nanocapsules) or in macroemulsions.
- colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano- particles and nanocapsules
- Sustained-release preparations may be prepared. Suitable examples of sustained- release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. films, or microcapsules.
- the formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.
- crenezumab reduced disease progression in patients suffering from AD.
- patients with mild to moderate AD including patients with mild AD and ApoE4 positive patients, as well as patients with brain amyloid load typically seen in patients diagnosed with AD, showed a reduction in the rate of cognitive decline when treated with crenezumab as compared to a placebo.
- the milder the disease based on increasing MMSE score, the greater the reduction in decline in the treatment arm as compared to the placebo arm.
- an antibody of the invention is used to treat AD, including mild to moderate AD, mild AD, and early AD.
- an antibody of the invention is used to treat an amyloidosis.
- the amyloidosis is mild cognitive impairment.
- the amyloidosis is Down's syndrome.
- the amyloidosis is hereditary cerebral hemorrhage with
- amyloidosis (Dutch type).
- amyloidosis is the Guam
- the amyloidosis is an ocular disease related to drusen or other amyloid deposit in the eye.
- the ocular disease is macular degeneration.
- the ocular disease is a drusen-related optic neuropathy.
- the ocular disease is glaucoma.
- the ocular disease is cataract.
- the antibody of the invention may be crenezumab.
- a patient is typically first assessed for the presence of one or more amyloidosis prior to determining the suitability of an antibody of the invention to treat such patient.
- AD may be diagnosed in a patient using the "NINCDS-ADRDA" (Neurological and Communicative Disorders and Stroke-Alzheimer's Disease Related Disorders Assessment) criteria. See McKhann, et ah, 1984, Neurology 34:939-44.
- a potential patient to be administered one or more antibodies of the invention may also be tested for the presence or absence of one or more genetic markers which may predispose such patient either to (i) a higher or lower likelihood of such patient experiencing one or more amyloidoses, or (ii) a higher or lower likelihood of such patient experiencing one or more adverse events or side effects during the course of administration of an antibody of the invention.
- one or more genetic markers which may predispose such patient either to (i) a higher or lower likelihood of such patient experiencing one or more amyloidoses, or (ii) a higher or lower likelihood of such patient experiencing one or more adverse events or side effects during the course of administration of an antibody of the invention.
- the antibody of the invention is used to treat mild to moderate AD in a patient.
- the patient can be ApoE4 positive or ApoE4 negative.
- the antibody of the invention is used to treat mild AD.
- the antibody of the invention is used to treat an ApoE4 positive patient suffering from mild to moderate AD or mild AD.
- the antibody of the invention is used to treat a patient suffering from mild AD.
- the antibody of the invention is used to treat a patient having an MMSE score of between 20 and 30, between 20 and 26, between 24 and 30, between 2 land 26, between 22 and 26, between 22 and 28, between 23 and 26, between 24 and 26, or between 25 and 26.
- the patient has an MMSE score between 22 and 26.
- an MMSE score between two numbers includes the numbers at each end of the range.
- an MMSE score between 22 and 26 includes MMSE scores of 22 and 26.
- the antibodies of the invention are used to treat a patient who is 'amyloid positive,' e.g., a patient having brain amyloid deposits that are typical of a patient diagnosed with AD or a patient having a positive florbetapir PET scan.
- the antibodies of the invention are used to reduce the accumulation of brain amyloid deposits or neuritic plaques ⁇ i.e., to reduce an increase in brain amyloid burden or load).
- the antibodies of the invention are useful for treating mild to moderate AD without increasing the incidence of ARIA-E or ARIA-H.
- the patients are suffering from mild AD.
- the patients are ApoE4 positive.
- the patients are ApoE4 positive and suffering from mild AD.
- the antibody of the invention is used to treat a patient with early AD.
- the patient to be treated has one or more of the following characteristics: (a) mild cognitive impairement (MCI) due to AD; (b) one or more biomarkers indicative of Alzheimer's Disease without a clinically detectable deficit; (c) an objective memory loss quantified using the Free and Cued Selective Reminding Test (FCSRT) as a score of 27 or greater; an MMSE of 24-30; (d) a global Clinical Dementia Rating (CDR) of 0.5; and (e) a positive amyloid PET scan (as determined by a qualified reader).
- MCI mild cognitive impairement
- CDR Clinical Dementia Rating
- methods for treating AD in a patient suffering from early, mild, or mild to moderate AD, comprising administering to said patient an anti-Abeta antibody in an amount effective to treat the AD, wherein the patient has at least on CLUSTERIN allele that comprises a T at SNP rsl532278 or an equivalent allele thereof.
- Methods, compositions, and tools for detecting or determining the presence or absence of a specific SNP are provided herein, see infra.
- Antibodies of the invention are formulated, dosed, and administered in a fashion consistent with good medical practice.
- Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual subject, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
- An antibody of the invention (and any additional therapeutic agent) can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration.
- Parenteral infusions include
- intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration is administered.
- Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic.
- the antibody is injected subcutaneously.
- the antibody is injected intravenously.
- the antibody is administered using a syringe (e.g., prefilled or not) or an autoinjector.
- the antibody is inhaled.
- an antibody of the invention when used alone or in combination with one or more other additional therapeutic agents, will depend on the specific type of disease to be treated, the type of antibody, the severity and course of the disease, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician.
- the antibody is suitably
- Various dosing schedules including, but not limited to, single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.
- about 0.3 mg/kg to 100 mg/kg (e.g. 15 mg/kg- 100 mg/kg, or any dosage within that range) of antibody can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion.
- One typical daily dosage might range from about 15 mg/kg to 100 mg/kg or more, depending on the factors mentioned above.
- the dosage can be administered in a single dose or a divided dose (e.g., two doses of 15 mg/kg for a total dose of 30 mg/ kg). For repeated administrations over several weeks or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs.
- One exemplary dosage of the antibody would be in the range from about 10 mg/kg to about 50 mg/kg.
- one or more doses of about 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 2.0 mg/kg, 3 mg/kg, 4.0 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 50 mg/ kg, 60 mg/ kg, 70 mg/kg, 80 mg/kg, 90 mg/kg, or 100 mg/kg (or any combination thereof) may be administered to the patient.
- the total dose administered is in the range of 50 mg to 2500 mg.
- An exemplary dose of about 50 mg, about 100 mg, 200 mg, 300 mg, 400 mg, about 500 mg, about 600 mg, about 700 mg, about 720 mg, about 1000 mg, about 1050 mg, about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, about 2000 mg, about 2050 mg, about 2100 mg, about 2200 mg, about 2300 mg, about 2400 mg, or about 2500 mg (or any combination thereof) may be administered to the patient.
- Such doses may be administered intermittently, e.g. every week, every two weeks, every three weeks, every four weeks, every month, every two months, every three months, or every six months.
- the patient receives from one to thirty five doses ⁇ e.g. about eighteen doses of the antibody).
- other dosage regimens may be useful. The progress of this therapy can be monitored by conventional techniques and assays.
- an antibody of the invention is administered at a dose of 15 mg/kg, 30 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 60 mg/kg or a flat dose, e.g., 300 mg, 500 mg, 700 mg, 800 mg, or higher.
- the dose is administered by intravenous injection every 2 weeks or every 4 weeks for a period of time.
- the dose is administered by subcutaneous injection every 2 weeks or every 4 weeks for a period of time.
- the period of time is 6 months, one year, eighteen months, two years, five years, ten years, 15 years, 20 years, or the lifetime of the patient.
- the antibody, or antigen-binding fragment hereof provides therapeutic effect or benefit to the patient.
- the therapeutic benefit is a delay in, or inihibition of, progression of AD or a reduction in clinical, functional, or cognitive decline.
- therapeutic effect or benefit is reflected in a "patient response” or “response” (and grammatical variations thereof).
- Patient response can be assessed using any endpoint indicating a benefit to the patient, including, without limitation, (1) inhibition, to some extent, of disease progression, including slowing down and complete arrest; (2) reduction in amount of plaque or reduction in brain amyloid accumulation; (3) improvement in one or more assessment metrics, including but not limited to ADAS-Cog, iADL, and CDR-SOB scales; (4) improvement in daily functioning of the patient; (5) increase in concentration of one or more biomarkers, e.g., Abeta, in cerebrospinal fluid; and (6) decrease in one or more biomarkers indicative of the presence of AD.
- An assessment of patient response may also include an assessment of any adverse events that may occur that may be correlated with the treatment.
- the cognitive ability and daily functioning of the patient is assessed prior to, during, and/or after a course of therapy with an antibody of the invention.
- a number of cognitive and functional assessment tools have been developed for use in assessing, diagnosing, and scoring mental function, cognition, and neurological deficit.
- ADAS-Cog including the 12 item ADAS-Cog (ADAS-Cogl2), the 13-item ADAS-Cog (ADAS-Cogl3), the 14-item ADAS-Cog (ADAS- Cog 14); the CDR-SOB, including CDR Judgment and Problem solving and CDR Memory components; the Instrumental Activities of Daily Living (iADL); and the MMSE.
- ADAS-Cog including the 12 item ADAS-Cog (ADAS-Cogl2), the 13-item ADAS-Cog (ADAS-Cogl3), the 14-item ADAS-Cog (ADAS- Cog 14); the CDR-SOB, including CDR Judgment and Problem solving and CDR Memory components; the Instrumental Activities of Daily Living (iADL); and the MMSE.
- ADAS-Cog refers to the Alzheimer's Disease Assessment Scale Cognitive Subscale, a multi-part cognitive assessment. See Rosen et al., 1984, Amer. J. Psych.
- ADAS-Cog may be used as one measure for assessing whether a treatment for AD is therapeutically effective. An increase in ADAS-Cog score is indicative of worsening in the patient's condition, whereas a decrease in ADAS-Cog score denotes improvement in the patient's condition.
- a "decline in ADAS-Cog performance” or an “increase in ADAS-Cog score” indicates a worsening in the patient's condition and may reflect progression of AD.
- the ADAS-Cog is an examiner-administered battery that assesses multiple cognitive domains, including memory, comprehension, praxis, orientation, and spontaneous speech (Rosen et al. 1984, Am J Psychiatr 141 : 1356-64; Mohs et al. 1997, Alzheimer Dis Assoc Disord 11(S2):S13-S21).
- the ADAS-Cog is a standard primary endpoint in AD treatment trials (Mani 2004, Stat Med 23:305-14).
- the ADAS-Cogl2 is the 70-point version of the ADAS-Cog plus a 10-point Delayed Word Recall item assessing recall of a learned word list.
- Other ADAS-Cog scales include the ADAS-Cogl3 and ADAS-Cogl4.
- the methods of treatment provided herein provide a reduction in cognitive decline as measured by an ADAS-Cog score that is at least about 30%, at least about 35%, at least about 40%, or at least about 45% lower relative to placebo.
- MMSE refers to the Mini Mental State Examination, which provides a score between 1 and 30. See Folstein, et ah, 1975, J. Psychiatr. Res. 12: 189-98. Scores of 26 and lower are generally considered to be indicative of a deficit. The lower the numerical score on the MMSE, the greater the tested patient's deficit or impairment relative to another individual with a lower score. An increase in MMSE score may be indicative of improvement in the patient's condition, whereas a decrease in MMSE score may denote worsening in the patient's condition.
- CDR-SOB refers to the Clinical Dementia Rating Scale / Sum of Boxes. See Hughes et al, 1982. CDR-assesses 6 components: memory, orientation, judgment/problem solving, community affairs, home and hobbies, and personal care. The test is administered to both the patient and the caregiver and each component (or each "box"), is scored on a scale of 0 to 3. A complete CDR-SOB score is based on the sum of the scores across all 6 boxes. Subscores can be obtained for each of the boxes or components individually as well, e.g., CDR/ Memory or CDR/ Judgment and Problem solving.
- a "decline in CDR- SOB performance” or an “increase in CDR-SOB score” indicates a worsening in the patient's condition and may reflect progression of AD.
- the methods of treatment provided herein provide a reduction in decline in CDR-SOB performance of at least about 30%), at least about 35%, or at least about 40% relative to placebo.
- iADL refers to the Instrumental Activities of Daily Living scale. See Lawton, M.P., and Brody, E.M., 1969, Gerontologist 9: 179-186. This scale measures the ability to perform typical daily activities such as housekeeping, laundry, operating a telephone, shopping, preparing meals, etc. The lower the score, the more impaired the individual is in conducting activities of daily living. In some embodiments, the methods of treatment provided herein provide a reduction in decline of at least about 10%, at least about 15%, or at least about 20% on the iADL scale relative to placebo.
- Brain amyloid load or burden can be determined using neurological imaging techniques and tools, for example using PET (positron emission tomography) scanning.
- PET positron emission tomography
- Serial PET scans of a patient taken over time e.g., before and after administration of a treatment (or at one or more intervals throughout the course of a treatment regimen) can permit detection of increased, decreased, or unchanged amyloid burden in the brain.
- This technique can further be used to determine whether amyloid accumulation is increasing or decreasing.
- detection of amyloid deposits in the brain is performed using florbetapir
- a florbetapir PET scan is considered positive if, based on a centralized visual read of the scan, it establishes the presence of moderate-to-frequent neuritic plaques.
- the antibody need not be, but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question or one or more of its symptoms.
- the effective amount of such other agents depends on the amount of antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate. It will be understood by one of ordinary skill in the art that an antibody of the invention may be co-administered simultaneously with any of the foregoing compounds, or may be administered prior to or subsequent to
- a neurological drug may be co-administered.
- Such neurological drug may be selected from the group including, but not limited to, an antibody or other binding molecule (including, but not limited to a small molecule, a peptide, an aptamer, or other protein binder) that specifically binds to a target selected from: beta secretase, tau, presenilin, amyloid precursor protein or portions thereof, amyloid beta peptide or oligomers or fibrils thereof, death receptor 6 (DR6), receptor for advanced glycation endproducts (RAGE), parkin, and huntingtin; a cholinesterase inhibitor (i.e., galantamine, donepezil, rivastigmine and tacrine); an NMDA receptor antagonist (i.e., memantine), a monoamine depletor (i.e., tetrabenazine); an ergoloid mesylate; an anticholinesterase inhibitor (i.e., galantamine, donepez
- antiparkinsonism agent i.e., entacapone, selegiline, pramipexole, bromocriptine, rotigotine, selegiline, ropinirole, rasagiline, apomorphine, carbidopa, levodopa, pergolide, tolcapone and amantadine
- a tetrabenazine an anti-inflammatory (including, but not limited to, a nonsteroidal anti-inflammatory drug (i.e., indomethicin and other compounds listed above); a hormone (i.e., estrogen, progesterone and leuprolide); a vitamin (i.e., folate and nicotinamide); a dimebolin; a homotaurine (i.e., 3-aminopropanesulfonic acid; 3APS); a serotonin receptor activity modulator (i.e., xaliproden); an, an interferon, and a glucocorticoi
- one or more anti-Abeta antibodies other than crenezumab are co-administered.
- Non-limiting examples of such anti-Abeta antibodies include solanezumab, bapineuzumab, aducanumab, and gantenerumab.
- corticosteroid includes, but is not limited to fluticasone (including fluticasone propionate (FP)), beclometasone, budesonide, ciclesonide, mometasone, flunisolide, betamethasone and triamcinolone.
- fluticasone including fluticasone propionate (FP)
- beclometasone a corticosteroid that is suitable for delivery by inhalation.
- Exemplary inhalable corticosteroids are fluticasone, beclomethasone dipropionate, budenoside, mometasone furoate, ciclesonide, flunisolide, and triamcinolone acetonide.
- a neurological drug may be selected that is an anti-angiogenic ophthalmic agent (i.e., bevacizumab, ranibizumab and pegaptanib), an ophthalmic glaucoma agent (i.e., carbachol, epinephrine, demecarium bromide, apraclonidine, brimonidine, brinzolamide, levobunolol, timolol, betaxolol, dorzolamide, bimatoprost, carteolol, metipranolol, dipivefrin, travoprost and latanoprost), a carbonic anhydrase inhibitor (i.e., methazolamide and acetazolamide), an ophthalmic antihistamine (i.e., naphazoline, phenylephrine and t
- an anti-angiogenic ophthalmic agent i.e., bevacizumab, ranibi
- an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above comprises a container and a label or package insert on or associated with the container.
- Suitable containers include, for example, bottles, vials, syringes, rV solution bags, etc.
- the containers may be formed from a variety of materials such as glass or plastic.
- the container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
- At least one active agent in the composition is an antibody of the invention.
- the label or package insert indicates that the composition is used for treating the condition of choice.
- the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises an antibody of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
- the article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition.
- the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
- BWFI bacteriostatic water for injection
- phosphate-buffered saline such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution.
- BWFI bacteriostatic water for injection
- phosphate-buffered saline such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution.
- BWFI bacteriostatic water for injection
- Ringer's solution such as phosphate
- any of the above articles of manufacture may include an immunoconjugate of the invention in place of or in addition to an anti-Abeta antibody.
- a method of reducing the decline in functional or cognitive capacity in a patient diagnosed with early or mild to moderate Alzheimer's Disease (AD) comprising
- a humanized monoclonal anti-amyloid beta ( ⁇ ) antibody that binds within residues 13 and 24 of amyloid ⁇ (1-42)(SEQ ID NO: l) in an amount effective to slow the decline in functional or cognitive capacity in the patient.
- HVRs hypervariable regions
- HVR-H1 is SEQ ID NO:2;
- HVR-H2 is SEQ ID NO:3;
- HVR-H3 is SEQ ID NO:4;
- HVR-L1 is SEQ ID NO:6;
- HVR-L2 is SEQ ID NO:7;
- HVR-L3 is SEQ ID NO:8.
- a method of treating early or mild to moderate AD without increasing the risk of an adverse event comprising administering to a patient diagnosed with early or mild to moderate AD an amount of a humanized monoclonal anti- ⁇ antibody that binds within residues 13 and 24 of amyloid ⁇ (1-42)(SEQ ID NO: l) that is effective to treat the AD without increasing the risk of a treatment emergent adverse event, wherein the adverse event is selected from: (i) Amyloid-Related Imaging Abnormality— Edema (ARIA-E) and (ii) Amyloid-Related Imaging Abnormality— Hemorrhage (ARIA-H).
- HVRs hypervariable regions
- HVR-H1 is SEQ ID NO:2;
- HVR-H2 is SEQ ID NO:3;
- HVR-H3 is SEQ ID NO:4;
- HVR-L1 is SEQ ID NO:6;
- HVR-L2 is SEQ ID N0:7;
- HVR-L3 is SEQ ID N0:8.
- a method of reducing the decline in functional or cognitive capacity in a patient diagnosed with early or mild to moderate Alzheimer's Disease (AD) comprising
- a humanized monoclonal anti-amyloid beta ( ⁇ ) antibody that binds within residues 13 and 24 of amyloid ⁇ (1-42)(SEQ ID NO: l) in an amount effective to slow the decline in functional or cognitive capacity in the patient.
- ⁇ monoclonal anti-amyloid beta
- the antibody is capable of binding oligomeric and monomeric forms of amyloid ⁇ .
- HVRs hypervariable regions
- HVR-H1 is SEQ ID NO:2;
- HVR-H2 is SEQ ID NO:3;
- HVR-H3 is SEQ ID NO:4;
- HVR-L1 is SEQ ID NO:6;
- HVR-L2 is SEQ ID NO:7;
- HVR-L3 is SEQ ID NO:8.
- ADAS-Cogl2 ADAS-Cogl3, or ADAS-Cogl4 test, optionally wherein the reduction in cognitive decline as measured by ADAS-Cog is at least 30%, at least 35%, at least 40%>, or at least 45% relative to placebo.
- a method of treating early or mild to moderate AD without increasing the risk of an adverse event comprising administering to an ApoE4 positive patient diagnosed with early or mild to moderate AD an amount of a humanized monoclonal anti- ⁇ antibody that binds within residues 13 and 24 of amyloid ⁇ (1-42)(SEQ ID NO: l) that is effective to treat the AD without increasing the risk of a treatment emergent adverse event, wherein the adverse event is selected from: (i) Amyloid-Related Imaging Abnormality— Edema (ARIA-E) and (ii) Amyloid-Related Imaging Abnormality— Hemorrhage (ARIA-H).
- HVRs hypervariable regions
- HVR-H1 is SEQ ID NO:2;
- HVR-H2 is SEQ ID NO:3;
- HVR-H3 is SEQ ID NO:4;
- HVR-L1 is SEQ ID NO:6;
- HVR-L2 is SEQ ID NO:7;
- HVR-L3 is SEQ ID NO:8. 50. The method of embodiment 49, wherein the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 5 and a light chain having the amino acid sequence of SEQ ID NO:9.
- any one of the preceding embodiments wherein the patient is concurrently treated with one or more agents selected from the group consisting of: a therapeutic agent that specifically binds to a target; a cholinesterase inhibitor; an NMDA receptor antagonist; a monoamine depletor; an ergoloid mesylate; an anticholinergic antiparkinsonism agent; a dopaminergic antiparkinsonism agent; a tetrabenazine; an antiinflammatory agent; a hormone; a vitamin; a dimebolin; a homotaurine; a serotonin receptor activity modulator; an interferon, and a glucocorticoid; an anti-Abeta antibody other than crenezumab; an antibiotic; an anti-viral agent.
- agents selected from the group consisting of: a therapeutic agent that specifically binds to a target; a cholinesterase inhibitor; an NMDA receptor antagonist; a monoamine depletor; an ergoloid mesy
- cholinesterase inhibitor is selected from the group consisting of galantamine, donepezil, rivastigmine and tacrine.
- the agent is a therapeutic agent that specifically binds to a target and the target is selected from the group consisting of beta secretase, tau, presenilin, amyloid precursor protein or portions thereof, amyloid beta peptide or oligomers or fibrils thereof, death receptor 6 (DR6), receptor for advanced glycation endproducts (RAGE), parkin, and huntingtin.
- DR6 death receptor 6
- RAGE receptor for advanced glycation endproducts
- antiparkinsonism agent selected from the group consisting of procyclidine, diphenhydramine, trihexylphenidyl, benztropine, biperiden and trihexyphenidyl.
- antiparkinsonism agent selected from the group consisting of: entacapone, selegiline, pramipexole, bromocriptine, rotigotine, selegiline, ropinirole, rasagiline, apomorphine, carbidopa, levodopa, pergolide, tolcapone and amantadine.
- agent is an anti-inflammatory agent selected from the group consisting of: a nonsteroidal anti-inflammatory drug and
- a method of slowing clinical decline in a patient diagnosed with early or mild to moderate Alzheimer's Disease comprising administering to a patient suffering from early or mild to moderate AD a humanized monoclonal anti-amyloid beta ( ⁇ ) antibody that binds within residues 13 and 24 of amyloid ⁇ (1-42)(SEQ ID NO: l) in an amount effective to slow the decline in the patient.
- ⁇ monoclonal anti-amyloid beta
- ⁇ monoclonal anti-amyloid beta
- HVRs hypervariable regions
- HVR-H1 is SEQ ID NO:2;
- HVR-H2 is SEQ ID NO:3;
- HVR-H3 is SEQ ID NO:4;
- HVR-L1 is SEQ ID NO:6;
- HVR-L2 is SEQ ID NO:7;
- HVR-L3 is SEQ ID NO:8.
- any one of embodiments 70 to 75 further comprising a decline in cognitive capacity assessed by determining the patient's score before and after administration of said antibody using a 12-item Alzheimer's Disease Assessment Scale - Cognition (ADAS- Cog ⁇ ), a 13-item Alzheimer's Disease Assessment Scale - Cognition (ADAS-Cogl3), or a 14-item Alzheimer's Disease Assessment Scale - Cognition (ADAS-Cogl2) test, optionally wherein the reduction in cognitive decline as measured by ADAS-Cog is at least 30%, at least 35%), at least 40%>, or at least 45% relative to placebo.
- ADAS-Cog ⁇ 12-item Alzheimer's Disease Assessment Scale - Cognition
- ADAS-Cogl3 13-item Alzheimer's Disease Assessment Scale - Cognition
- ADAS-Cogl2 14-item Alzheimer's Disease Assessment Scale - Cognition
- a method of treating early or mild AD in a subject comprising administering to a patient suffering from early or mild AD a humanized monoclonal anti-amyloid beta ( ⁇ ) antibody that binds within residues 13 and 24 of amyloid ⁇ (1-42)(SEQ ID NO: 1) in an amount effective to treat the AD.
- ⁇ monoclonal anti-amyloid beta
- HVRs hypervariable regions
- HVR-H1 is SEQ ID NO:2;
- HVR-H2 is SEQ ID NO:3;
- HVR-H3 is SEQ ID NO:4;
- HVR-L1 is SEQ ID NO:6;
- HVR-L2 is SEQ ID NO:7;
- HVR-L3 is SEQ ID NO : 8.
- ADAS-Cogl2 12-item Alzheimer's Disease Assessment Scale - Cognition
- ADAS-Cogl3 13-item Alzheimer's Disease Assessment Scale - Cognition
- ADAS-Cogl2 14-item Alzheimer's Disease Assessment Scale - Cognition
- a therapeutic agent that specifically binds to a target a cholinesterase inhibitor; an NMDA receptor antagonist; a monoamine depletor; an ergoloid mesylate; an anticholinergic antiparkinsonism agent; a dopaminergic antiparkinsonism agent; a tetrabenazine; an antiinflammatory agent; a hormone; a vitamin; a dimebolin; a homotaurine; a serotonin receptor activity modulator; an interferon, and a glucocorticoid; an anti-Abeta antibody; an antibiotic; an anti-viral agent.
- a therapeutic agent that specifically binds to a target a cholinesterase inhibitor
- an NMDA receptor antagonist a monoamine depletor
- an ergoloid mesylate an anticholinergic antiparkinsonism agent
- a dopaminergic antiparkinsonism agent a tetrabenazine
- an antiinflammatory agent a hormone
- cholinesterase inhibitor is selected from the group consisting of galantamine, donepezil, rivastigmine and tacrine.
- NMDA receptor antagonist is memantine or a salt thereof.
- the agent is a therapeutic agent that specifically binds to a target and the target is selected from the group consisting of beta secretase, tau, presenilin, amyloid precursor protein or portions thereof, amyloid beta peptide or oligomers or fibrils thereof, death receptor 6 (DR6), receptor for advanced glycation endproducts (RAGE), parkin, and huntingtin.
- the target is selected from the group consisting of beta secretase, tau, presenilin, amyloid precursor protein or portions thereof, amyloid beta peptide or oligomers or fibrils thereof, death receptor 6 (DR6), receptor for advanced glycation endproducts (RAGE), parkin, and huntingtin.
- DR6 death receptor 6
- RAGE receptor for advanced glycation endproducts
- antiparkinsonism agent selected from the group consisting of procyclidine, diphenhydramine, trihexylphenidyl, benztropine, biperiden and trihexyphenidyl.
- antiparkinsonism agent selected from the group consisting of: entacapone, selegiline, pramipexole, bromocriptine, rotigotine, selegiline, ropinirole, rasagiline, apomorphine, carbidopa, levodopa, pergolide, tolcapone and amantadine.
- agent is an anti-inflammatory agent selected from the group consisting of: a nonsteroidal anti-inflammatory drug and
- a method of treating Alzheimer's Disease (AD) in a patient suffering from early or mild to moderate AD comprising comprising administering to a patient suffering from early or mild to moderate AD a humanized monoclonal anti-amyloid beta ( ⁇ ) antibody in an amount effective to treat the AD, wherein the patient has at least one CLUSTERIN allele that comprises a T at the single nucleotide polymorphism (SNP) rsl532278.
- AD Alzheimer's Disease
- ⁇ single nucleotide polymorphism
- sample is a blood sample, saliva, cheek swab, tissue sample, or a sample of a bodily fluid.
- HVRs hypervariable regions
- HVR-H1 is SEQ ID NO:2;
- HVR-H2 is SEQ ID NO:3;
- HVR-H3 is SEQ ID NO:4;
- HVR-L1 is SEQ ID NO:6;
- HVR-L2 is SEQ ID NO:7;
- HVR-L3 is SEQ ID NO:8.
- anti-amyloid beta antibody is selected from the group consisting of solanezumab, bapineuzumab, aducanumab and gantenerumab.
- a method of selecting a patient suffering from early or mild to moderate AD for treatment with a humanized monoclonal anti-amyloid beta ( ⁇ ) antibody comprising:
- sample 140 is a blood sample, saliva, cheek swab, tissue sample, or a sample of a bodily fluid.
- MNPs magnetic nanoparticles
- RFLP methods restriction enzyme analysis of PCR products
- MPEX multiple primer extension
- isothermal smart amplification amplification on magnetic nanoparticles
- HVRs hypervariable regions
- HVR-H1 is SEQ ID NO:2;
- HVR-H2 is SEQ ID NO:3;
- HVR-H3 is SEQ ID NO:4;
- HVR-L1 is SEQ ID NO:6;
- HVR-L2 is SEQ ID NO:7;
- HVR-L3 is SEQ ID NO:8.
- anti-amyloid beta antibody is selected from the group consisting of solanezumab, bapineuzumab, aducanumab and gantenerumab.
- a method of identifying a patient suffering from early or mild to moderate AD as more likely to respond to treatment with a humanized monoclonal anti-amyloid beta ( ⁇ ) antibody comprising detecting in a sample from the patient presence of a CLUSTERIN allele comprising a polymorphism predictive of a response to treatment with a humanized monoclonal anti-amyloid beta ( ⁇ ) antibody.
- the polymorphism is a T at the single nucleotide polymorphism (SNP) rsl532278.
- sample 161 is a blood sample, saliva, cheek swab, tissue sample, or a sample of a bodily fluid.
- MNPs magnetic nanoparticles
- RFLP methods restriction enzyme analysis of PCR products
- MPEX multiple primer extension
- isothermal smart amplification amplification on magnetic nanoparticles
- HVRs hypervariable regions
- HVR-H1 is SEQ ID NO:2;
- HVR-H2 is SEQ ID NO:3;
- HVR-H3 is SEQ ID NO:4;
- HVR-L1 is SEQ ID NO:6;
- HVR-L2 is SEQ ID NO:7;
- HVR-L3 is SEQ ID NO:8.
- anti-amyloid beta antibody is selected from the group consisting of solanezumab, bapineuzumab, aducanumab and gantenerumab.
- a method of predicting whether an individual suffering from AD is likely to respond to treatment comprising an anti-Abeta antibody, or antigen-binding fragment thereof, comprising:
- HVRs hypervariable regions
- HVR-H1 is SEQ ID NO:2;
- HVR-H2 is SEQ ID NO:3;
- HVR-H3 is SEQ ID NO:4;
- HVR-L1 is SEQ ID NO:6;
- HVR-L2 is SEQ ID NO:7;
- HVR-L3 is SEQ ID NO : 8. 187.
- anti-amyloid beta antibody is selected from the group consisting of solanezumab, bapineuzumab, aducanumab, and gantenerumab.
- a method of optimizing therapeutic efficacy for treatment of AD comprising:
- determining the genotype of a patient wherein a patient who is determined to carry at least one CLUSTERIN allele with a T nucleotide at SNP rs 1532278 is more likely to respond to treatment with an anti-Abeta antibody, or antigen-binding fragment thereof.
- HVRs hypervariable regions
- HVR-H1 is SEQ ID NO:2;
- HVR-H2 is SEQ ID NO:3;
- HVR-H3 is SEQ ID NO:4;
- HVR-L1 is SEQ ID NO:6;
- HVR-L2 is SEQ ID NO:7;
- HVR-L3 is SEQ ID NO : 8.
- anti-amyloid beta antibody is selected from the group consisting of solanezumab, bapineuzumab, aducanumab and gantenerumab.
- a method for determining the likelihood that a patient suffering from AD will benefit from treatment comprising an anti-Abeta antibody, or antigen-binding fragment thereof comprising: determining the genotype of the patient, wherein the patient who has at least one CLUSTERIN allele with a T nucleotide at SNP rs 1532278 is more likely to respond to treatment with an anti-Abeta antibody than a patient who has no alleles with a T nucleotide at SNP rsl532278.
- HVRs hypervariable regions
- HVR-H2 is SEQ ID NO:3;
- HVR-H3 is SEQ ID NO:4;
- HVR-L1 is SEQ ID N0:6;
- HVR-L2 is SEQ ID N0:7;
- HVR-L3 is SEQ ID N0:8.
- anti-amyloid beta antibody is selected from the group consisting of solanezumab, bapineuzumab, aducanumab and gantenerumab.
- sample is a blood sample, saliva, cheek swab, tissue sample, or a sample of a bodily fluid.
- a kit for determining the presence of at least one polymorphism in a biological sample comprising reagents and instructions for detecting the presence of at least one polymorphism in CLUSTERIN, wherein the polymorphism is an allele comprising SNP rs 1532278 or an equivalent allele.
- kit of embodiment 220 wherein the kit is used to detect the presence of a T at SNP rsl532278.
- kits of embodiment 220, wherein the reagents comprise a set of oligonucleotides specific for detecting a polymorphism in CLUSTERIN.
- MNPs magnetic nanoparticles
- RFLP methods restriction enzyme analysis of PCR products
- MPEX multiple primer extension
- isothermal smart amplification amplification on magnetic nanoparticles
- EXAMPLE 1 ⁇ Clinical Study of Crenezumab, a Humanized Anti- ⁇ Monoclonal Antibody, in the Treatment of Mild to Moderate Alzheimer's Disease
- a randomized, double blind Phase II trial was conducted, using a placebo control, to evaluate the impact of the humanized monoclonal anti-amyloid beta (" ⁇ ") antibody crenezumab in patients diagnosed with mild to moderate Alzheimer's Disease (AD).
- Patients included in the study were, at the time of screening, between the ages of 50 and 80, and had a diagnosis of probable AD according to the NINCDS-ADRDA criteria with: a Mini-Mental State Examination (MMSE) score of 18 to 26 points, a Geriatric Depression Scale (GDS-15) score of less than 6, completion of 6 years of education (or good work history consistent with exclusion of mental retardation or other pervasive developmental disorders).
- MMSE Mini-Mental State Examination
- GDS-15 Geriatric Depression Scale
- AD treatment such as acetylcholinesterase inhibitors or memantine
- the patient was confirmed to have been on the medication for at least 3 months and at a stable dose for at least 2 months prior to randomization.
- At least 50% of the enrolled patients were ApoE4 positive (carrying at least one ApoE4 allele).
- non-anticholinergic antidepressant(s) such as non-anticholinergic antidepressant(s), atypical antipsychotic(s), non-benzodiazepine anxiolytic(s), soporific(s), centrally acting anticholinergic antihistamine(s), and centrally acting anticholinergic antispasmodic(s)
- non-anticholinergic antidepressant(s) such as atypical antipsychotic(s), non-benzodiazepine anxiolytic(s), soporific(s), centrally acting anticholinergic antihistamine(s), and centrally acting anticholinergic antispasmodic(s)
- the study had three periods - a screening period lasting up to 35 days, a treatment period lasting 68 weeks (referred to herein as Week 1, Week 2, etc., up to Week 69), and a safety follow-up period lasting a further 16 weeks (referred to herein as Week 70, etc., up to Week 85).
- Treatment or placebo was administered via intravenous infusion.
- a safety run-in assessment of 43 days was performed to determine the safety and tolerability of a 15 mg/kg intravenous dose versus a 10 mg/kg intravenous dose and a dose of 15 mg/kg was chosen.
- Patients in both arms of the trial received a blinded intravenous injection every four weeks for 68 weeks; based on the results of the safety run-in, patients in the treatment arm receive 15 mg/kg, while patients in the placebo arm received an
- crenezumab The safety and tolerability of crenezumab was assessed by measuring the frequency and severity of treatment emergent adverse events throughout the trial, especially instances of symptomatic or asymptomatic ARIA-E (including cerebral vasogenic edema), symptomatic or asymptomatic ARIA-H (including cerebral microhemorrhage), and cerebral macrohemorrhage.
- symptomatic or asymptomatic ARIA-E including cerebral vasogenic edema
- symptomatic or asymptomatic ARIA-H including cerebral microhemorrhage
- cerebral macrohemorrhage cerebral macrohemorrhage
- ADAS-Cogl2 measurements at 73 weeks demonstrate that patients received crenezumab showed less disease progression than patients who received placebo.
- FIG. 12A shows that when looking at the Memory or the Judgment and Problem solving component scores for patients having an MMSE of 22-26, the percent reduction was about 42% and 30% respectively.
- crenezumab did not increase the incidence of ARIA-type events when dosed at 15 mg/kg.
- a single, asymptomatic ARIA-E event was observed in the study, in a patient receiving crenezumab.
- the number of ARIA-H incidents was balanced between the treatment and placebo arms.
- crenezumab inhibits disease progression without increasing the incidence of a treatment emergent adverse event such as ARIA-E or ARIA-H when administered at a dose of 15 mg/kg in patients suffering from mild to moderate AD, particularly in patients with mild AD and/or who are ApoE4 positive.
- a randomized, double blind Phase II trial was conducted, using a placebo control, to evaluate the impact of the humanized monoclonal anti-amyloid beta (" ⁇ ") antibody crenezumab in patients diagnosed with mild to moderate Alzheimer's Disease (AD).
- Patients included in the study were, at the time of screening, between the ages of 50 and 80, and had a diagnosis of probable AD according to the NINCDS-ADRDA criteria with: a Mini-Mental State Examination (MMSE) score of 18 to 26 points, a Geriatric Depression Scale (GDS-15) score of less than 6, completion of 6 years of education (or good work history consistent with exclusion of mental retardation or other pervasive developmental disorders).
- MMSE Mini-Mental State Examination
- GDS-15 Geriatric Depression Scale
- florbetapir PET (“amyloid positive") scan at screening, indicative of increased brain amyloid load in the range expected for patients diagnosed with AD as assessed by florbetapir-PET scan, were enrolled. Additionally, at least 50% of the enrolled patients were ApoE4 positive.
- crenezumab engages its target, amyloid beta, and inhibits disease progression when administered at a dose of 15 mg/kg in patients suffering from mild to moderate AD, particularly in patients with mild AD, including in patients having a brain amyloid burden that is typical of that seen in patients diagnosed with AD.
- EXAMPLE 3 Study of Single Nucleotide Polymorphisms in a Clinical Study of Crenezumab, a Humanized Anti- ⁇ Monoclonal Antibody, Associated with Treatment
- a randomized, double blind Phase II trial was conducted, using a placebo control, to evaluate the impact of the humanized monoclonal anti-amyloid beta (" ⁇ ") antibody crenezumab in patients diagnosed with mild to moderate Alzheimer's Disease (AD).
- Patients included in the study were, at the time of screening, between the ages of 50 and 80, and had a diagnosis of probable AD according to the NINCDS-ADRDA criteria with: a Mini-Mental State Examination (MMSE) score of 18 to 26 points, a Geriatric Depression Scale (GDS-15) score of less than 6, completion of 6 years of education (or good work history consistent with exclusion of mental retardation or other pervasive developmental disorders).
- MMSE Mini-Mental State Examination
- GDS-15 Geriatric Depression Scale
- AD treatment such as acetylcholinesterase inhibitors or memantine
- the patient was confirmed to have been on the medication for at least 3 months and at a stable dose for at least 2 months prior to randomization.
- At least 50% of the enrolled patients were ApoE4 positive (carrying at least one ApoE4 allele).
- non-anticholinergic antidepressant(s) such as non-anticholinergic antidepressant(s), atypical antipsychotic(s), non-benzodiazepine anxiolytic(s), soporific(s), centrally acting anticholinergic antihistamine(s), and centrally acting anticholinergic antispasmodic(s)
- non-anticholinergic antidepressant(s) such as atypical antipsychotic(s), non-benzodiazepine anxiolytic(s), soporific(s), centrally acting anticholinergic antihistamine(s), and centrally acting anticholinergic antispasmodic(s)
- the study had three periods - a screening period lasting up to 35 days, a treatment period lasting 68 weeks (referred to herein as Week 1, Week 2, etc., up to Week 69), and a safety follow-up period lasting a further 16 weeks (referred to herein as Week 70, etc., up to Week 85).
- Treatment or placebo was administered via intravenous infusion.
- genotype data were analyzed to control for genotyping errors and quality as follows.
- Single nucleotide polymorphisms SNPs with > 50% genotyping rate were retained for further analysis. SNPs that did not meet assay quality control standards described below were removed from consideration as were subgroups that did not represent between 25% to 75%) of the study population with SNP results. For quality control purposes, samples with >10% overall missing data were excluded. Individual variants with >5% missing data were excluded from further analysis.
- the remaining variants were tested for cryptic relatedness (via IBD estimation)(Laurie et al., 2010, Genet Epidemiology 34(6):591-602) and for sample contamination (via excess heterozygosity testing in a representative subset of the variants) as described in Turner et al. , 2011 , Curr Protoc Hum Genet Chapter 1 :Unitl .19.
- the mean change in ADAS-Cogl2 at week 73 in the treatment arm vs the placebo arm was assessed using two genetic models of inheritance.
- the ADAS-Cogl2 mean change over time was contrasted between a group consisting of risk allele homozygous and heterozygous carriers in the treatment arm vs all individuals in the placebo arm using a linear regression model (as described in Lynch, et ah, GENETICS AND ANALYSIS OF QUANTITATIVE TRAITS (Sunderland, MA, Sinauer, 1998)).
- ADAS-Cogl2 mean change over time was contrasted between a group consisting of protective allele homozygous and heterozygous carriers in the treatment arm vs all individuals in the placebo using the same linear regression model.
- ADAS- Cogl2 change over time was designated as the outcome of interest and group status as a predictor variable.
- the significance of group status as a predictor variable was assessed using a t-statistic and a two-sided p-value.
- MMRM Mixed model repeated measures
- Results A total of 19 variants previously associated with risk of developing AD were tested for a predictive effect on response to crenuzumab treatment.
- SNPs were identified having a p value of 0.06 or less for the association of either a risk allele or a protective allele with a treatment effect based on the the estimated treatment delta in ADAS- Cogl2 at week 73 between the treatment arm and the placebo arm.
- One of the SNPs identified was rs 1532278 from the CLUSTERIN (CLU, also known as ApoJ) gene where being a carrier for the protective allele, T, had potentially enhanced treatment effects.
- CLUSTERIN CLUSTERIN
- the estimated treatment delta in ADAS-Cogl2 at week 73 was 3.45 in the SNP positive population (individuals having at least one protective allele) versus -0.78 in the SNP negative population (individuals having no protective allele). These represent percent reductions in the crenezumab arm relative to the placebo arm of 35.9% for SNP positive vs -7.4% for SNP negative patients. See FIG. 16A-B. Further analysis of the CLUSTERIN SNP within the ApoE4 positive population (FIG. 17A-B) and Mild (MMSE 20-26) population (FIG. 18A-B) showed similar results.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15706100.3A EP3102230B1 (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease |
RU2016132162A RU2720468C2 (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease |
CA2938731A CA2938731A1 (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease |
BR112016018205A BR112016018205A8 (en) | 2014-02-08 | 2015-02-06 | methods of treating alzheimer's disease, patient selection, patient identification, prediction, therapeutic efficacy optimization, kit, agent use and in vitro agent use |
KR1020167024494A KR102476641B1 (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease |
AU2015213741A AU2015213741B2 (en) | 2014-02-08 | 2015-02-06 | Methods of treating Alzheimer's Disease |
PL15706100T PL3102230T3 (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease |
ES15706100T ES2873248T3 (en) | 2014-02-08 | 2015-02-06 | Methods to treat Alzheimer's disease |
EP21162693.2A EP3900738A1 (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease |
JP2016550546A JP6702878B2 (en) | 2014-02-08 | 2015-02-06 | How to treat Alzheimer's disease |
SG11201606490YA SG11201606490YA (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease |
MX2016010237A MX2016010237A (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease. |
CN201580018454.4A CN106456729A (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease |
IL247085A IL247085B (en) | 2014-02-08 | 2016-08-03 | Methods of treating alzheimer's disease |
US15/239,225 US20170369559A9 (en) | 2014-02-08 | 2016-08-17 | Methods of treating alzheimer's disease |
AU2020233696A AU2020233696A1 (en) | 2014-02-08 | 2020-09-16 | Methods of treating Alzheimer's Disease |
US17/330,898 US20220098288A1 (en) | 2014-02-08 | 2021-05-26 | Methods of treating alzheimer's disease |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461937472P | 2014-02-08 | 2014-02-08 | |
US61/937,472 | 2014-02-08 | ||
US201461971499P | 2014-03-27 | 2014-03-27 | |
US61/971,499 | 2014-03-27 | ||
US201462010265P | 2014-06-10 | 2014-06-10 | |
US62/010,265 | 2014-06-10 | ||
US201462082013P | 2014-11-19 | 2014-11-19 | |
US62/082,013 | 2014-11-19 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/239,225 Continuation US20170369559A9 (en) | 2014-02-08 | 2016-08-17 | Methods of treating alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015120280A1 true WO2015120280A1 (en) | 2015-08-13 |
Family
ID=52574436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/014829 WO2015120280A1 (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease |
Country Status (16)
Country | Link |
---|---|
US (2) | US20170369559A9 (en) |
EP (2) | EP3900738A1 (en) |
JP (3) | JP6702878B2 (en) |
KR (1) | KR102476641B1 (en) |
CN (2) | CN112826930A (en) |
AU (2) | AU2015213741B2 (en) |
BR (1) | BR112016018205A8 (en) |
CA (1) | CA2938731A1 (en) |
ES (1) | ES2873248T3 (en) |
IL (1) | IL247085B (en) |
MX (2) | MX2016010237A (en) |
PL (1) | PL3102230T3 (en) |
RU (2) | RU2720468C2 (en) |
SG (2) | SG11201606490YA (en) |
TW (3) | TWI785472B (en) |
WO (1) | WO2015120280A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017127764A1 (en) * | 2016-01-20 | 2017-07-27 | Genentech, Inc. | High dose treatments for alzheimer's disease |
WO2018005282A1 (en) | 2016-07-01 | 2018-01-04 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
WO2018023036A1 (en) * | 2016-07-29 | 2018-02-01 | Biogen Chesapeake Llc | Methods of treating or preventing amyloid related imaging abnormalities associated with alzheimer's disease treatment |
CN108779167A (en) * | 2015-10-28 | 2018-11-09 | 宾夕法尼亚州大学信托人 | Intrathecal application adeno-associated virus vector is used for gene therapy |
WO2022109267A3 (en) * | 2020-11-19 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Genotyping by sequencing |
US11434284B2 (en) | 2020-07-23 | 2022-09-06 | Othair Prothena Limited | Anti-Abeta antibodies |
WO2022261510A1 (en) * | 2021-06-11 | 2022-12-15 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of alzheimer's disease |
US11878995B2 (en) | 2016-05-06 | 2024-01-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
US11905309B2 (en) | 2013-03-13 | 2024-02-20 | Sage Therapeutics, Inc. | Neuroactive steroids and methods of use thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10779762B2 (en) * | 2015-10-20 | 2020-09-22 | Washington University | MRI method for in vivo detection of amyloid and pathology in the Alzheimer brain |
JP2019020206A (en) * | 2017-07-14 | 2019-02-07 | 株式会社島津製作所 | Cognitive disorder biomarker quantification method using mass analysis and mass spectroscope |
US11058729B2 (en) * | 2018-01-25 | 2021-07-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Exosomes and miRNA to treat glaucoma |
KR102555878B1 (en) * | 2020-04-23 | 2023-07-17 | 주식회사 바이오오케스트라 | Use of downregulated mirna for diagnosis and treatment |
JP2023525859A (en) * | 2020-05-14 | 2023-06-19 | ザ・ホンコン・ユニバーシティー・オブ・サイエンス・アンド・テクノロジー | Protein markers for determining Alzheimer's disease |
WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
Citations (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0404097A2 (en) | 1989-06-22 | 1990-12-27 | BEHRINGWERKE Aktiengesellschaft | Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof |
WO1993001161A1 (en) | 1991-07-11 | 1993-01-21 | Pfizer Limited | Process for preparing sertraline intermediates |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US5492806A (en) | 1987-04-01 | 1996-02-20 | Hyseq, Inc. | Method of determining an ordered sequence of subfragments of a nucleic acid fragment by hybridization of oligonucleotide probes |
US5500362A (en) | 1987-01-08 | 1996-03-19 | Xoma Corporation | Chimeric antibody with specificity to human B cell surface antigen |
US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5589330A (en) | 1994-07-28 | 1996-12-31 | Genzyme Corporation | High-throughput screening method for sequence or genetic alterations in nucleic acids using elution and sequencing of complementary oligonucleotides |
US5624821A (en) | 1987-03-18 | 1997-04-29 | Scotgen Biopharmaceuticals Incorporated | Antibodies with altered effector functions |
US5648237A (en) | 1991-09-19 | 1997-07-15 | Genentech, Inc. | Expression of functional antibody fragments |
WO1997030087A1 (en) | 1996-02-16 | 1997-08-21 | Glaxo Group Limited | Preparation of glycosylated antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5821337A (en) | 1991-06-14 | 1998-10-13 | Genentech, Inc. | Immunoglobulin variants |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5849483A (en) | 1994-07-28 | 1998-12-15 | Ig Laboratories, Inc. | High throughput screening method for sequences or genetic alterations in nucleic acids |
WO1998058964A1 (en) | 1997-06-24 | 1998-12-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
WO1999051642A1 (en) | 1998-04-02 | 1999-10-14 | Genentech, Inc. | Antibody variants and fragments thereof |
US6001611A (en) | 1997-03-20 | 1999-12-14 | Roche Molecular Systems, Inc. | Modified nucleic acid amplification primers |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO2000052625A2 (en) | 1999-02-22 | 2000-09-08 | Vialogy Corporation | Method and apparatus for analyzing hybridized biochip patterns using resonance interactions |
WO2000061739A1 (en) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6152681A (en) | 1996-05-03 | 2000-11-28 | Arrowhead Systems, Llc | Container sweep for a palletizer and method |
US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6197506B1 (en) | 1989-06-07 | 2001-03-06 | Affymetrix, Inc. | Method of detecting nucleic acids |
WO2001025485A2 (en) | 1999-10-06 | 2001-04-12 | Amersham Biosciences Corp | Method for detecting mutations using arrayed primer extension |
US6223127B1 (en) | 1997-08-15 | 2001-04-24 | Affymetrix, Inc. | Polymorphism detection utilizing clustering analysis |
WO2001029246A1 (en) | 1999-10-19 | 2001-04-26 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
WO2001029259A2 (en) | 1999-10-18 | 2001-04-26 | Affymetrix, Inc. | Identification of alleles |
US6225625B1 (en) | 1989-06-07 | 2001-05-01 | Affymetrix, Inc. | Signal detection methods and apparatus |
US6229911B1 (en) | 1997-07-25 | 2001-05-08 | Affymetrix, Inc. | Method and apparatus for providing a bioinformatics database |
US6239273B1 (en) | 1995-02-27 | 2001-05-29 | Affymetrix, Inc. | Printing molecular library arrays |
US6248516B1 (en) | 1988-11-11 | 2001-06-19 | Medical Research Council | Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
WO2002031140A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions |
US6420548B1 (en) | 1999-10-04 | 2002-07-16 | Medicago Inc. | Method for regulating transcription of foreign genes |
US20020164328A1 (en) | 2000-10-06 | 2002-11-07 | Toyohide Shinkawa | Process for purifying antibody |
WO2003011878A2 (en) | 2001-08-03 | 2003-02-13 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
US20030115614A1 (en) | 2000-10-06 | 2003-06-19 | Yutaka Kanda | Antibody composition-producing cell |
US6602684B1 (en) | 1998-04-20 | 2003-08-05 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
US6627402B2 (en) | 1992-06-17 | 2003-09-30 | City Of Hope | Method of detecting and discriminating between nucleic acid sequences |
WO2003085107A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells with modified genome |
WO2003084570A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM |
WO2003085119A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20040109865A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
US20040110282A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
WO2004056312A2 (en) | 2002-12-16 | 2004-07-08 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
US20050014934A1 (en) | 2002-10-15 | 2005-01-20 | Hinton Paul R. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
WO2005035778A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF α1,6-FUCOSYLTRANSFERASE |
WO2005035586A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
US20050119455A1 (en) | 2002-06-03 | 2005-06-02 | Genentech, Inc. | Synthetic antibody phage libraries |
US20050123546A1 (en) | 2003-11-05 | 2005-06-09 | Glycart Biotechnology Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
WO2005053742A1 (en) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicine containing antibody composition |
WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
US20050260186A1 (en) | 2003-03-05 | 2005-11-24 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20050266000A1 (en) | 2004-04-09 | 2005-12-01 | Genentech, Inc. | Variable domain library and uses |
US6982321B2 (en) | 1986-03-27 | 2006-01-03 | Medical Research Council | Altered antibodies |
US20060025576A1 (en) | 2000-04-11 | 2006-02-02 | Genentech, Inc. | Multivalent antibodies and uses therefor |
WO2006029879A2 (en) | 2004-09-17 | 2006-03-23 | F.Hoffmann-La Roche Ag | Anti-ox40l antibodies |
WO2006044908A2 (en) | 2004-10-20 | 2006-04-27 | Genentech, Inc. | Antibody formulation in histidine-acetate buffer |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7087409B2 (en) | 1997-12-05 | 2006-08-08 | The Scripps Research Institute | Humanization of murine antibody |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
US7189826B2 (en) | 1997-11-24 | 2007-03-13 | Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
US20070061900A1 (en) | 2000-10-31 | 2007-03-15 | Murphy Andrew J | Methods of modifying eukaryotic cells |
US20070117126A1 (en) | 1999-12-15 | 2007-05-24 | Genentech, Inc. | Shotgun scanning |
US20070160598A1 (en) | 2005-11-07 | 2007-07-12 | Dennis Mark S | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
US20070292936A1 (en) | 2006-05-09 | 2007-12-20 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
US20080069820A1 (en) | 2006-08-30 | 2008-03-20 | Genentech, Inc. | Multispecific antibodies |
US7371826B2 (en) | 1999-01-15 | 2008-05-13 | Genentech, Inc. | Polypeptide variants with altered effector function |
WO2008077546A1 (en) | 2006-12-22 | 2008-07-03 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
US20090002360A1 (en) | 2007-05-25 | 2009-01-01 | Innolux Display Corp. | Liquid crystal display device and method for driving same |
US7521541B2 (en) | 2004-09-23 | 2009-04-21 | Genetech Inc. | Cysteine engineered antibodies and conjugates |
US7527791B2 (en) | 2004-03-31 | 2009-05-05 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
US20100099110A1 (en) | 2008-10-20 | 2010-04-22 | Roche Molecular Systems, Inc. | Allele-Specific Amplification |
WO2014009733A2 (en) * | 2012-07-11 | 2014-01-16 | The University Of Birmingham | Therapeutic targets for alzheimer's disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2007002070A1 (en) | 2006-07-14 | 2008-02-08 | Ac Immune S A Genentech Inc | CHEMERIC OR HUMANIZED ANTIBODY, OR FRAGMENTS OF THEM, WHICH SPECIFICALLY ADHER TO AT LEAST AN EPITHOPE IN THE BETA-AMYLOID PROTEIN; NUCLEIC ACID MOLECULA THAT CODIFIES IT; COMPOSITION THAT UNDERSTANDS IT; YOUR USE TO TREAT NURSING |
CN101611054B (en) | 2006-10-02 | 2013-12-25 | Ac免疫有限公司 | Humanized antibody against amyloid beta |
JO3076B1 (en) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
CN102229651A (en) * | 2011-06-08 | 2011-11-02 | 中南大学 | Amyloid protein intra-membrane segment for treating Alzheimer disease and application thereof |
-
2015
- 2015-02-06 TW TW110102168A patent/TWI785472B/en active
- 2015-02-06 CA CA2938731A patent/CA2938731A1/en active Pending
- 2015-02-06 JP JP2016550546A patent/JP6702878B2/en active Active
- 2015-02-06 WO PCT/US2015/014829 patent/WO2015120280A1/en active Application Filing
- 2015-02-06 TW TW111100089A patent/TW202239429A/en unknown
- 2015-02-06 BR BR112016018205A patent/BR112016018205A8/en not_active Application Discontinuation
- 2015-02-06 SG SG11201606490YA patent/SG11201606490YA/en unknown
- 2015-02-06 CN CN202110043649.1A patent/CN112826930A/en active Pending
- 2015-02-06 ES ES15706100T patent/ES2873248T3/en active Active
- 2015-02-06 MX MX2016010237A patent/MX2016010237A/en unknown
- 2015-02-06 AU AU2015213741A patent/AU2015213741B2/en active Active
- 2015-02-06 RU RU2016132162A patent/RU2720468C2/en active
- 2015-02-06 CN CN201580018454.4A patent/CN106456729A/en active Pending
- 2015-02-06 EP EP21162693.2A patent/EP3900738A1/en active Pending
- 2015-02-06 EP EP15706100.3A patent/EP3102230B1/en active Active
- 2015-02-06 SG SG10201901076WA patent/SG10201901076WA/en unknown
- 2015-02-06 PL PL15706100T patent/PL3102230T3/en unknown
- 2015-02-06 RU RU2020111676A patent/RU2020111676A/en unknown
- 2015-02-06 TW TW104104200A patent/TWI769970B/en active
- 2015-02-06 KR KR1020167024494A patent/KR102476641B1/en active IP Right Grant
-
2016
- 2016-08-03 IL IL247085A patent/IL247085B/en active IP Right Grant
- 2016-08-05 MX MX2020010947A patent/MX2020010947A/en unknown
- 2016-08-17 US US15/239,225 patent/US20170369559A9/en not_active Abandoned
-
2019
- 2019-12-20 JP JP2019230686A patent/JP2020090497A/en not_active Withdrawn
-
2020
- 2020-09-16 AU AU2020233696A patent/AU2020233696A1/en not_active Abandoned
-
2021
- 2021-05-26 US US17/330,898 patent/US20220098288A1/en not_active Abandoned
- 2021-11-08 JP JP2021181553A patent/JP2022036946A/en active Pending
Patent Citations (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6982321B2 (en) | 1986-03-27 | 2006-01-03 | Medical Research Council | Altered antibodies |
US5500362A (en) | 1987-01-08 | 1996-03-19 | Xoma Corporation | Chimeric antibody with specificity to human B cell surface antigen |
US5648260A (en) | 1987-03-18 | 1997-07-15 | Scotgen Biopharmaceuticals Incorporated | DNA encoding antibodies with altered effector functions |
US5624821A (en) | 1987-03-18 | 1997-04-29 | Scotgen Biopharmaceuticals Incorporated | Antibodies with altered effector functions |
US5492806A (en) | 1987-04-01 | 1996-02-20 | Hyseq, Inc. | Method of determining an ordered sequence of subfragments of a nucleic acid fragment by hybridization of oligonucleotide probes |
US6018041A (en) | 1987-04-01 | 2000-01-25 | Hyseq, Inc. | Method of sequencing genomes by hybridization of oligonucleotide probes |
US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
US5695940A (en) | 1987-04-01 | 1997-12-09 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
US6248516B1 (en) | 1988-11-11 | 2001-06-19 | Medical Research Council | Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors |
US6225625B1 (en) | 1989-06-07 | 2001-05-01 | Affymetrix, Inc. | Signal detection methods and apparatus |
US6197506B1 (en) | 1989-06-07 | 2001-03-06 | Affymetrix, Inc. | Method of detecting nucleic acids |
EP0404097A2 (en) | 1989-06-22 | 1990-12-27 | BEHRINGWERKE Aktiengesellschaft | Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6417429B1 (en) | 1989-10-27 | 2002-07-09 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5821337A (en) | 1991-06-14 | 1998-10-13 | Genentech, Inc. | Immunoglobulin variants |
WO1993001161A1 (en) | 1991-07-11 | 1993-01-21 | Pfizer Limited | Process for preparing sertraline intermediates |
US5648237A (en) | 1991-09-19 | 1997-07-15 | Genentech, Inc. | Expression of functional antibody fragments |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
US6627402B2 (en) | 1992-06-17 | 2003-09-30 | City Of Hope | Method of detecting and discriminating between nucleic acid sequences |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US5849483A (en) | 1994-07-28 | 1998-12-15 | Ig Laboratories, Inc. | High throughput screening method for sequences or genetic alterations in nucleic acids |
US5589330A (en) | 1994-07-28 | 1996-12-31 | Genzyme Corporation | High-throughput screening method for sequence or genetic alterations in nucleic acids using elution and sequencing of complementary oligonucleotides |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US6239273B1 (en) | 1995-02-27 | 2001-05-29 | Affymetrix, Inc. | Printing molecular library arrays |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
WO1997030087A1 (en) | 1996-02-16 | 1997-08-21 | Glaxo Group Limited | Preparation of glycosylated antibodies |
US6152681A (en) | 1996-05-03 | 2000-11-28 | Arrowhead Systems, Llc | Container sweep for a palletizer and method |
US6001611A (en) | 1997-03-20 | 1999-12-14 | Roche Molecular Systems, Inc. | Modified nucleic acid amplification primers |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
WO1998058964A1 (en) | 1997-06-24 | 1998-12-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6229911B1 (en) | 1997-07-25 | 2001-05-08 | Affymetrix, Inc. | Method and apparatus for providing a bioinformatics database |
US6223127B1 (en) | 1997-08-15 | 2001-04-24 | Affymetrix, Inc. | Polymorphism detection utilizing clustering analysis |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US7189826B2 (en) | 1997-11-24 | 2007-03-13 | Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
US7087409B2 (en) | 1997-12-05 | 2006-08-08 | The Scripps Research Institute | Humanization of murine antibody |
WO1999051642A1 (en) | 1998-04-02 | 1999-10-14 | Genentech, Inc. | Antibody variants and fragments thereof |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6602684B1 (en) | 1998-04-20 | 2003-08-05 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US7371826B2 (en) | 1999-01-15 | 2008-05-13 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7332581B2 (en) | 1999-01-15 | 2008-02-19 | Genentech, Inc. | Polypeptide variants with altered effector function |
WO2000052625A2 (en) | 1999-02-22 | 2000-09-08 | Vialogy Corporation | Method and apparatus for analyzing hybridized biochip patterns using resonance interactions |
US6136541A (en) | 1999-02-22 | 2000-10-24 | Vialogy Corporation | Method and apparatus for analyzing hybridized biochip patterns using resonance interactions employing quantum expressor functions |
WO2000061739A1 (en) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6420548B1 (en) | 1999-10-04 | 2002-07-16 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
WO2001025485A2 (en) | 1999-10-06 | 2001-04-12 | Amersham Biosciences Corp | Method for detecting mutations using arrayed primer extension |
WO2001029259A2 (en) | 1999-10-18 | 2001-04-26 | Affymetrix, Inc. | Identification of alleles |
WO2001029246A1 (en) | 1999-10-19 | 2001-04-26 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
US20070117126A1 (en) | 1999-12-15 | 2007-05-24 | Genentech, Inc. | Shotgun scanning |
US20060025576A1 (en) | 2000-04-11 | 2006-02-02 | Genentech, Inc. | Multivalent antibodies and uses therefor |
US20030115614A1 (en) | 2000-10-06 | 2003-06-19 | Yutaka Kanda | Antibody composition-producing cell |
US20020164328A1 (en) | 2000-10-06 | 2002-11-07 | Toyohide Shinkawa | Process for purifying antibody |
WO2002031140A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions |
US20070061900A1 (en) | 2000-10-31 | 2007-03-15 | Murphy Andrew J | Methods of modifying eukaryotic cells |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
WO2003011878A2 (en) | 2001-08-03 | 2003-02-13 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
WO2003085107A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells with modified genome |
WO2003084570A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM |
WO2003085119A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa |
US20040109865A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
US20040110282A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
US20050119455A1 (en) | 2002-06-03 | 2005-06-02 | Genentech, Inc. | Synthetic antibody phage libraries |
US20050014934A1 (en) | 2002-10-15 | 2005-01-20 | Hinton Paul R. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2004056312A2 (en) | 2002-12-16 | 2004-07-08 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
US20050260186A1 (en) | 2003-03-05 | 2005-11-24 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
WO2005035586A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
WO2005035778A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF α1,6-FUCOSYLTRANSFERASE |
US20050123546A1 (en) | 2003-11-05 | 2005-06-09 | Glycart Biotechnology Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
WO2005053742A1 (en) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicine containing antibody composition |
US7527791B2 (en) | 2004-03-31 | 2009-05-05 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
US20050266000A1 (en) | 2004-04-09 | 2005-12-01 | Genentech, Inc. | Variable domain library and uses |
WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
WO2006029879A2 (en) | 2004-09-17 | 2006-03-23 | F.Hoffmann-La Roche Ag | Anti-ox40l antibodies |
US7521541B2 (en) | 2004-09-23 | 2009-04-21 | Genetech Inc. | Cysteine engineered antibodies and conjugates |
WO2006044908A2 (en) | 2004-10-20 | 2006-04-27 | Genentech, Inc. | Antibody formulation in histidine-acetate buffer |
US20070160598A1 (en) | 2005-11-07 | 2007-07-12 | Dennis Mark S | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
US20070292936A1 (en) | 2006-05-09 | 2007-12-20 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
US20080069820A1 (en) | 2006-08-30 | 2008-03-20 | Genentech, Inc. | Multispecific antibodies |
WO2008077546A1 (en) | 2006-12-22 | 2008-07-03 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
US20090002360A1 (en) | 2007-05-25 | 2009-01-01 | Innolux Display Corp. | Liquid crystal display device and method for driving same |
WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
US20100099110A1 (en) | 2008-10-20 | 2010-04-22 | Roche Molecular Systems, Inc. | Allele-Specific Amplification |
WO2014009733A2 (en) * | 2012-07-11 | 2014-01-16 | The University Of Birmingham | Therapeutic targets for alzheimer's disease |
Non-Patent Citations (158)
Title |
---|
"Crenezumab Phase II cognition data in Alzheimer's disease presented", 16 July 2014 (2014-07-16), XP055183813, Retrieved from the Internet <URL:http://www.acimmune.com/content/img/pages/ACImmune_crenezumab_phase2_ENGLISH_20140716_final.pdf> [retrieved on 20150417] * |
"Current Protocols In Molecular Biology", 1995 |
"Methods in Molecular Biology, Single Nucleotide Polymorphisms", 2009, HUMANA PRESS |
"Remington's Pharmaceutical Sciences", 1980 |
ALMAGRO; FRANSSON, FRONT. BIOSCI., vol. 13, 2008, pages 1619 - 1633 |
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1995, WILEY INTERSCIENCE PUBLISHERS |
BACA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 10678 - 10684 |
BARBAS ET AL., PROC NAT. ACAD. SCI, USA, vol. 91, 1994, pages 3809 - 3813 |
BOERNER ET AL., J. IMMUNOL., vol. 147, 1991, pages 86 |
BOERNER ET AL.: "J. Immunol.", vol. 147, 1991, pages: 86 |
BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 |
BRODEUR ET AL.: "Monoclonal Antibody Production Techniques and Applications", 1987, MARCEL DEKKER, INC., pages: 51 - 63 |
BRODEUR ET AL.: "Monoclonal Antibody Production Techniques and Applications", 1987, MARCEL DEKKER, INC., pages: 55 - 93 |
BROOKMEYER ET AL., ALZHEIMERS DEMENT., vol. 3, 2007, pages 186 - 91 |
BRUGGEMANN, M., J. EXP. MED., vol. 166, 1987, pages 1351 - 1361 |
BRUGGERMANN, YEAR IN IMMUNOL., vol. 7, 1993, pages 33 |
CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285 |
CHALELA JA; GOMES J., EXPERT REV. NEUROTHER., vol. 4, 2004, pages 267 |
CHARLOTTE JAGO: "Alzheimer's Disease: One Year Later", 3 February 2014 (2014-02-03), XP055183816, Retrieved from the Internet <URL:http://lsconnect.thomsonreuters.com/alzheimers-disease-year-later/> [retrieved on 20150417] * |
CHARLTON: "Methods in Molecular Biology", vol. 248, 2003, HUMANA PRESS, pages: 245 - 254 |
CHEN ET AL., J. MOL. BIOL., vol. 293, 1999, pages 865 - 881 |
CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
CHOWDHURY, METHODS MOL. BIOL., vol. 207, 2008, pages 179 - 196 |
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628 |
CLARKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628 |
CLYNES ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 95, 1998, pages 652 - 656 |
CRAGG, M.S. ET AL., BLOOD, vol. 101, 2003, pages 1045 - 1052 |
CRAGG, M.S.; M.J. GLENNIE, BLOOD, vol. 103, 2004, pages 2738 - 2743 |
CRONIN ET AL., HUM MUTAT, vol. 7, no. 3, 1996, pages 244 - 55 |
CUMMINGS, N. ENGL. J. MED., vol. 351, 2004, pages 56 - 67 |
CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085 |
DALL'ACQUA ET AL., METHODS, vol. 36, 2005, pages 43 - 60 |
DEANE ET AL., STROKE, vol. 35, no. I, 2004, pages 2628 - 31 |
DESHPANDE ET AL., CURRENT PROTOCOL IN HUMAN GENETICS, 2005, pages 13.4.1 - 13.4.11 |
DUNCAN; WINTER, NATURE, vol. 322, 1988, pages 738 - 40 |
FELLOUSE, PROC. NATL. ACAD. SCI. USA, vol. 101, no. 34, 2004, pages 12467 - 12472 |
FLATMAN ET AL., J. CHROMATOGR. B, vol. 848, 2007, pages 79 - 87 |
FOLSTEIN ET AL., J. PSYCHIATR. RES., vol. 12, 1975, pages 189 - 98 |
GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, vol. 202, 1996, pages 163 |
GERNGROSS, NAT. BIOTECH., vol. 22, 2004, pages 1409 - 1414 |
GLENNER; WONG, BIOCHEM BIOPHYS RES. COMM., vol. 129, 1984, pages 885 - 890 |
GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59 |
GREENBERG ET AL., LANCET NEUROL., vol. 8, 2009, pages 165 - 74 |
GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734 |
GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368 |
GUYER ET AL., J. IMMUNOL., vol. 117, 1976, pages 587 |
HAASS; SELKOE, NATURE, vol. 8, 2007, pages 656 - 67 |
HARLOW; LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY |
HARRIS, BIOCHEM. SOC. TRANSACTIONS, vol. 23, 1995, pages 1035 - 1038 |
HAWKINS ET AL., J. MOL. BIOL., vol. 226, 1992, pages 889 - 896 |
HEBERT ET AL., ARCH. NEUROL., vol. 60, 2003, pages 1119 - 22 |
HELLSTROM, 1. ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 83, 1986, pages 7059 - 7063 |
HELLSTROM, I, PROC. NAT'L ACAD. SCI. USA, vol. 82, 1985, pages 1499 - 1502 |
HOLLAND ET AL., P.N.A.S. USA, vol. 88, 1991, pages 7276 - 7280 |
HOLLAND ET AL., PROC. NATL. ACAD. SCI., vol. 88, 1991, pages 7276 - 7280 |
HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448 |
HOOGENBOOM ET AL., NUCL. ACIDS RES., vol. 19, 1991, pages 4133 - 4137 |
HOOGENBOOM ET AL.: "Methods in Molecular Biology", vol. 178, 2001, HUMAN PRESS, pages: 1 - 37 |
HOOGENBOOM; WINTER, J. MOL. BIOL., vol. 227, 1992, pages 381 - 388 |
HUDSON ET AL., NAT. MED, vol. 9, 2003, pages 129 - 134 |
HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134 |
HURLE; GROSS, CURR. OP. BIOTECH., vol. 5, 1994, pages 428 - 433 |
IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178 - 4184 |
JACKSON ET AL., J. IMMUNOL., vol. 154, no. 7, 1995, pages 3310 - 9 |
JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 |
JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI USA, vol. 90, 1993, pages 2551 |
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525 |
JOSHUA M SHULMAN ET AL: "Online-only Material Genetic susceptibility for Alzheimer's disease neuritic plaque pathology", 1 September 2013 (2013-09-01), XP055183842, Retrieved from the Internet <URL:http://dejager_lab.bwh.harvard.edu/wp-content/uploads/2013/02/Shulman-et-al-2013_-Online-1.pdf> [retrieved on 20150417] * |
JOSHUA M. SHULMAN ET AL: "Genetic Susceptibility for Alzheimer Disease Neuritic Plaque Pathology", JAMA NEUROLOGY, vol. 70, no. 9, 1 September 2013 (2013-09-01), pages 1150, XP055183924, ISSN: 2168-6149, DOI: 10.1001/jamaneurol.2013.2815 * |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", vol. 1-3, 1991, NIH PUBLICATION 91-3242 |
KAM ET AL., PROC. NATL. ACAD. SCI. USA, vol. 102, 2005, pages 11600 - 11605 |
KANDA, Y. ET AL., BIOTECHNOL. BIOENG., vol. 94, no. 4, 2006, pages 680 - 688 |
KAROLIEN BETTENS ET AL: "Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk", MOLECULAR NEURODEGENERATION, BIOMED CENTRAL LTD, LO, vol. 7, no. 1, 16 January 2012 (2012-01-16), pages 3, XP021119144, ISSN: 1750-1326, DOI: 10.1186/1750-1326-7-3 * |
KASHMIRI ET AL., METHODS, vol. 36, 2005, pages 25 - 34 |
KIM ET AL., J. IMMUNOL., vol. 24, 1994, pages 249 |
KINDT ET AL.: "Kuby Immunology", 2007, W.H. FREEMAN AND CO., pages: 91 |
KLIMKA ET AL., BR. J. CANCER, vol. 83, 2000, pages 252 - 260 |
KOSTELNY ET AL., J. IMMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553 |
KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001 |
KUMARA-N, AM J NEURORADIOL., vol. 31, 2010, pages 5 |
KWOK ET AL., CURRENT PROTOCOL IN HUMAN GENETICS, 2003, pages 2.11.L - 2.11.10 |
L. LANNFELT ET AL: "Amyloid-ß-directed immunotherapy for Alzheimer's disease", JOURNAL OF INTERNAL MEDICINE, vol. 275, no. 3, 8 March 2014 (2014-03-08), pages 284 - 295, XP055183709, ISSN: 0954-6820, DOI: 10.1111/joim.12168 * |
LAMBERT ET AL., CURRENT PROTOCOL IN HUMAN GENETICS, 2013, pages 2.9.1 - 2.9.3 |
LAURIE ET AL., GENET EPIDEMIOLOGY, vol. 34, no. 6, 2010, pages 591 - 602 |
LAWTON, M.P.; BRODY, E.M., GERONTOLOGIST, vol. 9, 1969, pages 179 - 186 |
LEE ET AL., J. IMMUNOL. METHODS, vol. 284, no. 1-2, 2004, pages 119 - 132 |
LEE ET AL., J. MOL. BIOL., vol. 340, no. 5, 2004, pages 1073 - 1093 |
LI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 3557 - 3562 |
LI, NAT. BIOTECH., vol. 24, 2006, pages 210 - 215 |
LONBERG, CURR. OPIN. IMMUNOL., vol. 20, 2008, pages 450 - 459 |
LONBERG, NAT. BIOTECH., vol. 23, 2005, pages 1117 - 1125 |
LYNCH ET AL.: "GENETICS AND ANALYSIS OF QUANTITATIVE TRAITS", 1998, SINAUER |
MANI, STAT MED, vol. 23, 2004, pages 305 - 14 |
MARCH: "Advanced Organic Chemistry Reactions, Mechanisms and Structure", 1992, JOHN WILEY & SONS |
MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783 |
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597 |
MARKS ET AL., J. MOL. BIOL., vol. 222, 1992, pages 581 - 597 |
MARKS; BRADBURY: "Methods in Molecular Biology", vol. 248, 2003, HUMAN PRESS, pages: 161 - 175 |
MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68 |
MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251 |
MCCAFFERTY ET AL., NATURE, vol. 348, pages 552 - 554 |
MCKHANN ET AL., NEUROLOGY, vol. 34, 1984, pages 939 - 44 |
MILES ET AL., SCIENTIFIC REPORTS, vol. 3, 2013, pages 1 - 4 |
MILSTEIN; CUELLO, NATURE, vol. 305, 1983, pages 537 |
MOHS ET AL., ALZHEIMER DIS ASSOC DISORD, vol. 11, no. S2, 1997, pages S13 - S21 |
MOHS ET AL., ALZHEIMER'S DISEASE ASSOC. DISORDERS, vol. 11, no. 2, 1997, pages 513 - 521 |
MORGAN, NEURODEGENER. DIS., vol. 2, 2005, pages 261 - 6 |
MORRIS: "Methods in Molecular Biology", vol. 66, 1996, HUMANA PRESS, article "Epitope Mapping Protocols" |
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855 |
NI, XIANDAI MIANYIXUE, vol. 26, no. 4, 2006, pages 265 - 268 |
OKAZAKI ET AL., J. MOL. BIOL., vol. 336, 2004, pages 1239 - 1249 |
OLIPHANT ET AL., BIOTECHNIQUES, 2002, pages 60 - 1 |
OSBOURN ET AL., METHODS, vol. 36, 2005, pages 61 - 68 |
PADLAN, MOL. IMMUNOL., vol. 28, 1991, pages 489 - 498 |
PETKOVA, S.B. ET AL., INT'L. IMMUNOL., vol. 18, no. 12, 2006, pages 1759 - 1769 |
PLUCKTHUN: "The Pharmacology of Monoclonal Antibodies", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315 |
PORTOLANO ET AL., J. IMMUNOL., vol. 150, 1993, pages 880 - 887 |
PREKUMAR ET AL., AM. J PATHOL., vol. 148, 1996, pages 2083 - 95 |
PREKUMAR ET AL., AM. J. PATHOL., vol. 148, 1996, pages 2083 - 95 |
PRESTA ET AL., CANCER RES., vol. 57, 1997, pages 4593 - 4599 |
PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623 |
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596 |
QUEEN ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033 |
RACHELLE S. DOODY ET AL: "Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease", NEW ENGLAND JOURNAL OF MEDICINE, vol. 370, no. 4, 23 January 2014 (2014-01-23), pages 311 - 321, XP055183832, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1312889 * |
RAVETCH; KINET, ANNU. REV. IMMUNOL., vol. 9, 1991, pages 457 - 492 |
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329 |
RIPKA ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 249, 1986, pages 533 - 545 |
ROSEN ET AL., AM J PSYCHIATR, vol. 141, 1984, pages 1356 - 64 |
ROSEN ET AL., AMER. J. PSYCH., vol. 141, 1984, pages 1356 - 1364 |
ROSOK ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 22611 - 22618 |
SALLOWAY ET AL., N. ENGL. J. MED., vol. 370, 2014, pages 322 - 333 |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR PRESS |
SAMBROOK, J.; RUSSELL, D.W.: "Molecular Cloning", 2001, CSHL PRESS |
SAUNDERS ET AL., NEUROLOGY, vol. 43, 1993, pages 1467 - 72 |
SCHIER ET AL., GENE, vol. 169, 1996, pages 147 - 155 |
SHEN ET AL., MUTAT RES, vol. 573, no. 1-2, 2005, pages 70 - 82 |
SHIELDS, J. BIOL. CHEM., vol. 9, no. 2, 2001, pages 6591 - 6604 |
SIDHU ET AL., J. MOL. BIOL., vol. 338, no. 2, 2004, pages 299 - 310 |
SIMS, J. IMMUNOL., vol. 151, 1993, pages 2296 |
SINGLETON: "Dictionary of Microbiology and Molecular Biology", 1994, J. WILEY & SONS |
SPERLING ET AL., ALZHEIMER'S & DEMENTIA, vol. 7, 2011, pages 367 |
SPERLING ET AL., ALZHEIMER'S & DEMENTIA, vol. 7, 2011, pages 367 - 385 |
SPERLING ET AL., THE LANCET, vol. 11, 2012, pages 241 - 249 |
TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655 |
TURNER ET AL.: "Curr Protoc Hum Genet", 2011 |
TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60 |
URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 |
VAN DIJK; VAN DE WINKEL, CURR. OPIN. PHARMACOL., vol. 5, 2001, pages 368 - 74 |
VASWANI; HAMILTON, ANN. ALLERGY, ASTHMA & IMMUNOL., vol. 1, 1998, pages 105 - 115 |
VOLLMERS; BRANDLEIN, HISTOLOGY AND HISTOPATHOLOGY, vol. 20, no. 3, 2005, pages 927 - 937 |
VOLLMERS; BRANDLEIN, METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol. 27, no. 3, 2005, pages 185 - 91 |
WARREN ET AL., CURRENT PROTOCOL IN HUMAN GENETICS, 2001, pages 7.4.1 - 7.4.23 |
WINTER ET AL., ANN. REV. IMMUNOL., vol. 12, 1994, pages 433 - 455 |
WRIGHT ET AL., TIBTECH, vol. 15, 1997, pages 26 - 32 |
YAMANE-OHNUKI ET AL., BIOTECH. BIOENG., vol. 87, 2004, pages 614 |
YAZAKI; WU: "Methods in Molecular Biology", vol. 248, 2003, HUMANA PRESS, pages: 255 - 268 |
YELTON ET AL., J. IMMUNOL., vol. 155, 1995, pages 1994 - 2004 |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11905309B2 (en) | 2013-03-13 | 2024-02-20 | Sage Therapeutics, Inc. | Neuroactive steroids and methods of use thereof |
CN108779167A (en) * | 2015-10-28 | 2018-11-09 | 宾夕法尼亚州大学信托人 | Intrathecal application adeno-associated virus vector is used for gene therapy |
US11135313B2 (en) | 2015-10-28 | 2021-10-05 | The Trustees Of The University Of Pennsylvania | Intrathecal administration of adeno-associated-viral vectors for gene therapy |
JP2019501115A (en) * | 2015-10-28 | 2019-01-17 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Intrathecal administration of adeno-associated virus vector for gene therapy |
CN108602883A (en) * | 2016-01-20 | 2018-09-28 | 基因泰克公司 | High-dose therapy for Alzheimer's disease |
WO2017127764A1 (en) * | 2016-01-20 | 2017-07-27 | Genentech, Inc. | High dose treatments for alzheimer's disease |
US11878995B2 (en) | 2016-05-06 | 2024-01-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
WO2018005282A1 (en) | 2016-07-01 | 2018-01-04 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
WO2018023036A1 (en) * | 2016-07-29 | 2018-02-01 | Biogen Chesapeake Llc | Methods of treating or preventing amyloid related imaging abnormalities associated with alzheimer's disease treatment |
US11434284B2 (en) | 2020-07-23 | 2022-09-06 | Othair Prothena Limited | Anti-Abeta antibodies |
US11434283B2 (en) | 2020-07-23 | 2022-09-06 | Othair Prothena Limited | Anti-abeta antibodies |
US11434285B2 (en) | 2020-07-23 | 2022-09-06 | Othair Prothena Limited | Anti-Abeta antibodies |
US11440953B2 (en) | 2020-07-23 | 2022-09-13 | Othair Prothena Limited | Anti-abeta antibodies |
WO2022109267A3 (en) * | 2020-11-19 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Genotyping by sequencing |
WO2022261510A1 (en) * | 2021-06-11 | 2022-12-15 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of alzheimer's disease |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220098288A1 (en) | Methods of treating alzheimer's disease | |
US20220195020A1 (en) | Methods of treating alzheimer's disease | |
US20240076358A1 (en) | High dose treatments for alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15706100 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2938731 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 247085 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2016550546 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/010237 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016018205 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2015213741 Country of ref document: AU Date of ref document: 20150206 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20167024494 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016132162 Country of ref document: RU Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015706100 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015706100 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112016018205 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160808 |